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ABSTRACT 
 
This work was carried out in the Department of Biochemistry Faculty of 
Veterinary Medicine University of Khartoum. Samples were collected from 
patients visiting hospitals in Khartoum State during the period (1/1/2004 
untill 1/9/2004). The aim of the study is to investigate the effect of disease 
condition on blood levels of certain tumor markers namely CEA, CA15-3 
and on other plasma constituents which are discovered to be affected during 
malignancy, the plasma total cholesterol and triacylglycerols levels. One 
hundred and sixty five females were employed in this study. Five groups of 
disease conditions were studied. Primary breast cancer, advanced breast 
cancer, benign breast tumors, cancer conditions (other than breast cancer) 
and non-cancer diseases conditions. Results were compared to a group of 
clinically healthy females as control. The study considered also clinical 
parameters associated with breast cancer e.g. lymph node involvement, 
nipple discharge, the size of the tumor and breast ulcerations. 
The study revealed the following findings: 
• The level of the CEA was reported to be higher in all disease 
conditions compared to control, but the only significant (P<0.05) 
difference was found in the group of other cancer conditions 
patients. 
• The CA15-3 showed also higher levels in all disease conditions 
compared to control and in the primary and advanced breast cancer 
conditions, the levels were significantly higher (P<0.05) compared to 
control. 
• The plasma total cholesterol showed lower levels in all disease 
conditions with significantly (P<0.01) lower levels in primary breast 
cancer and other cancer conditions. The advanced breast cancer was 
an exception and reported significantly (P<0.01) higher levels 
compared to control.  
• The triacylglycerols levels were higher in non-cancer diseases, 
advanced breast cancer and the other cancer conditions with a highly 
significant (P<0.01) difference in the non-cancer disease conditions. 
The benign and primary breast tumors groups showed lower levels 
compared to control. 
When the clinical parameters were considered in primary breast cancer 
group: 
• Lymph node involvement resulted in very high levels of CEA 
compared to control. In contrast significantly (P<0.01) higher levels 
 6
of CA1-3 were reported in the group of no lymph node involvement 
compared to the level of the control. Cholesterol and triacylglycerols 
were not affected. 
• Tumor size, it was found that, when the size is larger than 5 cm, it 
results in higher levels of CEA and CA15-3, compared to control. 
The difference was highly significant (P<0.01) for the levels of 
CA15-3 marker. The levels of cholesterol and triacylglycerols were 
not affected. 
• Breast ulcerations resulted in higher levels of CEA in patients 
compared to control. In contrast CA15-3 reported significantly 
(P<0.01) higher levels in the cases of no breast ulcerations. Plasma 
cholesterol and triacylglycerols were not affected. 
• Nipple discharge resulted in very high level of CEA compared to 
control. In contrast cases of no nipple discharge recorded 
significantly (P<0.01) higher level, of CA15-3 tumor marker, 
compared to control. Cholesterol levels were not affected in both 
cancer groups, but triacylglycerols levels reported significantly 
(P<0.01) lower levels in the group of no nipple discharge. 
• Findings in the present work suggest a reduction of the levels of 
CA15-3 tumor marker when the case of breast cancer is complicated. 
 
In this study, the percentages of patients who recorded abnormally high 
levels of the tumor markers CEA and CA15-3, from the total of breast 
cancer patients, were higher compared to values reported in previous studies. 
Further studies exploring about tumor markers, in larger numbers of 
Sudanese patients, may confirm this finding.           
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 ﻣﻠﺨﺺ اﻷﻃﺮوﺣﺔ
 ﺟﺎﻣﻌﺔ اﻟﺨﺮﻃﻮم ﺣﻴﺚ ﺗﻢ – آﻠﻴﺔ اﻟﻄﺐ اﻟﺒﻴﻄﺮي – ﻓﻲ ﻗﺴﻢ اﻟﻜﻴﻤﻴﺎء اﻟﺤﻴﻮﻳﺔ ﻪﺗﻢ ﻋﻤﻞ هﺬﻩ اﻟﺪر اﺳ
 4002/1/1 ﻣﻦ ﻣﺮﺿﻰ ﺑﻤﺴﺘﺸﻔﻴﺎت وﻻﻳﺔ اﻟﺨﺮﻃﻮم ﺧﻼل اﻟﻔﺘﺮة ﻣﺎ ﺑﻴﻦ ﻪﺟﻤﻊ ﻋﻴﻨﺎت هﺬﻩ اﻟﺪر اﺳ
ت اﻟﺪم ﺑﺎﻟﻨﺴﺒﺔ  هﻮ ﻣﻌﺮﻓﺔ أﺛﺮ اﻟﺤﺎﻟﺔ اﻟﻤﺮﺿﻴﺔ ﻋﻠﻲ ﻣﻌﺪﻻﻪاﻟﻬﺪف ﻣﻦ هﺬﻩ اﻟﺪر اﺳ. 4002/9/1ﺣﺘﻰ 
 ﺗﻢ ﺑﺎﻷﺿﺎﻓﻪ ﻟﺒﻌﺾ ﻣﻜﻮﻧﺎت اﻟﺪم اﻷﺧﺮى  اﻟﺘﻲ  3-51AC و AECﻟﺒﻌﺾ ﻣﻮّﺳﻤﺎت اﻷورام وهﻲ 
ﺗﻢ إﺧﻀﺎع .إﺛﺒﺎت ﺗﺄﺛﺮهﺎ ﺑﺤﺎﻻت اﻟﺴﺮﻃﺎن ﻣﺜﻞ ﻣﻌﺪﻻت اﻟﻜﻮﻟﺴﺘﺮول اﻟﻜﻠﻲ و اﻟﺠﻠﺴﺮﻳﺪات اﻟﺜﻼﺛﻴﺔ 
ﺳﺘﻬﺎ ﻣﺎ ﺑﻴﻦ ﺗﺮاوﺣﺖ اﻟﺤﺎﻻت أﻟﻤﺮﺿﻴﻪ اﻟﺘﻲ ﺗﻤﺖ درا. ﻪﻣﺌﺔ وﺧﻤﺴﺔ وﺳﺘﻮن ﺳّﻴﺪﻩ ﻟﻬﺬﻩ اﻟﺪر اﺳ
ﻏﻴﺮ )ﺳﺮﻃﺎن اﻟﺜﺪي اﻷوﻟﻲ، ﺳﺮﻃﺎن اﻟﺜﺪي اﻟﻤﺘﻘﺪم، أورام اﻟﺜﺪي اﻟﺤﻤﻴﺪة، ﺣﺎﻻت اﻟﺴﺮﻃﺎن اﻷﺧﺮى 
ﺗﻤﺖ ﻣﻘﺎرﻧﺔ اﻟﻨﺘﺎﺋﺞ اﻟﺘﻲ ﺗﻢ (. ﻏﻴﺮ اﻟﺴﺮﻃﺎﻧﻴﺔ)و ﺑﻌﺾ اﻷﻣﺮاض اﻷﺧﺮى اﻟﺤﻤﻴﺪﻩ ( ﺳﺮﻃﺎن اﻟﺜﺪي
ﻤﺠﻤﻮﻋﺔ  ﻣﻊ ﻣﺠﻤﻮﻋﺔ ﻣﻦ اﻟﺴﻴﺪات اﻟﺨﺎﻟﻴﺎت ﻣﻦ أي ﻣﺮض آﻪاﻟﺤﺼﻮل ﻋﻠﻴﻬﺎ ﻣﻦ هﺬﻩ اﻟﺪر اﺳ
 أﻳﻀﺎ ﻋﻠﻲ اﻷﺧﺬ ﺑﺎﻻﻋﺘﺒﺎر ﻟﺒﻌﺾ اﻟﻤﺆﺷﺮات أﻹآﻠﻴﻨﻴﻜﻴﻪ ﻟﻤﺮض ﻪاﺷﺘﻤﻠﺖ هﺬﻩ اﻟﺪر اﺳ. ﺿﺎﺑﻄﻪ
ﺣﺠﻢ اﻟﻮرم و , وﺟﻮد إﻓﺮازات ﺧﻼل اﻟﺤﻠﻤﻪ, ﺳﺮﻃﺎن اﻟﺜﺪي ﻣﺜﻞ وﺻﻮل اﻟﻤﺮض ﻟﻠﻐﺪد أﻟﻠﻴﻤﻔﺎوﻳﻪ
  .وﺟﻮد ﺗﻘﺮﺣﺎت ﻓﻲ اﻟﺜﺪي
  :وﻗﺪ ﺳﺠﻠﺖ هﺬﻩ اﻟﺪراﺳﻪ اﻟﻨﺘﺎﺋﺞ اﻟﺘﺎﻟﻴﻪ
 ﻣѧﺴﺘﻮﻳﺎت ﻋﺎﻟﻴѧﻪ ﻓѧﻲ آѧﻞ اﻟﺤѧﺎﻻت اﻟﻤﺮﺿѧﻴﻪ ﻣﻘﺎرﻧѧﺔ ﻣѧﻊ AECﺳѧﺠﻠﺖ ﻣﻌѧﺪﻻت اﻟﻤﻮّﺳѧﻢ  •
وﺟﺪ ﻓﻘﻂ ﻓﻲ ﻣﺮﺿѧﻲ اﻟﺤѧﺎﻻت ( 50.0<P)اﻟﻤﺠﻤﻮﻋﻪ اﻟﻀﺎﺑﻄﺔ وﻟﻜﻦ اﻹﺧﺘﻼف اﻟﻤﻌﻨﻮي 
 (.ﻏﻴﺮ ﺳﺮﻃﺎن اﻟﺜﺪي)اﻟﺴﺮﻃﺎﻧﻴﻪ 
  أﻳѧﻀﺎ ﻣѧﺴﺘﻮﻳﺎت ﻋﺎﻟﻴѧﻪ ﻓѧﻲ آѧﻞ اﻟﺤѧﺎﻻت اﻟﻤﺮﺿѧﻴﻪ 3-51ACﺳѧﺠﻠﺖ ﻣﻌѧﺪﻻت اﻟﻤﻮّﺳѧﻢ  •
 ﻣﺮﺿﻲ ﺳﺮﻃﺎن اﻟﺜѧﺪي اﻷوﻟѧﻲ و اﻟﻤﺘﻘѧﺪم ﻣﻘﺎرﻧﺔ ﻣﻊ اﻟﻤﺠﻤﻮﻋﻪ اﻟﻀﺎﺑﻄﺔ واﻟﻤﻌﺪﻻت  ﻓﻲ 
 . ﻣﻘﺎرﻧﺔ ﻣﻊ اﻟﻤﺠﻤﻮﻋﻪ اﻟﻀﺎﺑﻄﺔ(  50.0<P)إرﺗﻔﻌﺖ ﺑﻤﺴﺘﻮي ﻣﻌﻨﻮي 
ﻣﻌﺪﻻت اﻟﻜﻮﻟﺴﺘﺮول اﻟﻜﻠﻴﺔ ﺳﺠﻠﺖ ﻣﻌѧﺪﻻت ﻣﻨﺨﻔѧﻀﻪ  ﻓѧﻲ آѧﻞ اﻟﺤѧﺎﻻت اﻟﻤﺮﺿѧﻴﻪ وﻟﻜѧﻦ  •
وﺟѧѧﺪ ﻓѧѧﻲ ﻣﺮﺿѧѧﻲ ﺳѧѧﺮﻃﺎن اﻟﺜѧѧﺪي اﻷوﻟѧѧﻲ و اﻟﺤѧѧﺎﻻت ( 50.0<P)اﻹﺧѧѧﺘﻼف اﻟﻤﻌﻨѧѧﻮي
أﻣѧѧﺎ ﺣѧѧﺎﻻت ﺳѧѧﺮﻃﺎن اﻟﺜѧѧﺪي اﻟﻤﺘﻘѧѧﺪم أوردت إرﺗﻔﺎﻋѧѧﺎ . ياﻟѧѧﺴﺮﻃﺎﻧﻴﻪ ﻏﻴѧѧﺮ ﺳѧѧﺮﻃﺎن اﻟﺜѧѧﺪ
 .   ﻣﻘﺎرﻧﺔ ﻣﻊ اﻟﻤﺠﻤﻮﻋﻪ اﻟﻀﺎﺑﻄﺔ(  10.0<P)إﺳﺘﺜﻨﺎﺋﻴﺎ و وﻣﻌﻨﻮﻳﺎ 
ﺳѧѧﺠﻠﺖ ﻣﻌѧѧﺪﻻت اﻟﺠﻠѧѧﺴﺮﻳﺪات اﻟﺜﻼﺛﻴѧѧﺔ ﻣѧѧﺴﺘﻮﻳﺎت ﻋﺎﻟﻴѧѧﻪ ﻓѧѧﻲ ﺣѧѧﺎﻻت اﻷﻣѧѧﺮاض اﻷﺧѧѧﺮى  •
ﺳѧѧﺮﻃﺎن اﻟﺜѧѧﺪي اﻟﻤﺘﻘѧѧﺪم و ﻓѧѧﻲ ﻣﺮﺿѧѧﻲ اﻟﺤѧѧﺎﻻت اﻟѧѧﺴﺮﻃﺎﻧﻴﻪ , (ﻏﻴѧѧﺮ اﻟѧѧﺴﺮﻃﺎﻧﻴﺔ)اﻟﺤﻤﻴѧѧﺪﻩ 
( ﻏﻴѧﺮ اﻟѧﺴﺮﻃﺎﻧﻴﺔ)وأوردت ﺣѧﺎﻻت اﻷﻣѧﺮاض اﻷﺧѧﺮى اﻟﺤﻤﻴѧﺪﻩ (. ﺳѧﺮﻃﺎن اﻟﺜѧﺪيﻏﻴѧﺮ )
 .   ﻣﻘﺎرﻧﺔ ﻣﻊ اﻟﻤﺠﻤﻮﻋﻪ اﻟﻀﺎﺑﻄﺔ(  10.0<P)إرﺗﻔﺎﻋﺎ ﻣﻌﻨﻮﻳﺎ آﺒﻴﺮا 
وﻋﻨﺪ أﺧﺬ اﻟﻤﺆﺷﺮات أﻹآﻠﻴﻨﻴﻜﻴﻪ ﻟﻤﺮض ﺳﺮﻃﺎن اﻟﺜﺪي ﻋﻴﻦ اﻹﻋﺘﺒﺎر وذﻟﻚ ﻋﻨﺪ ﻣﺮﺿﻲ 
  :وﺟﺪ اﻵﺗﻲ, ﺳﺮﻃﺎن اﻟﺜﺪي اﻷوﻟﻲ
ﻠﻴﻤﻔﺎوﻳѧﻪ اﻟѧﻲ ﻇﻬѧﻮر ﻣѧﺴﺘﻮﻳﺎت ﻋﺎﻟﻴѧﻪ ﺟѧﺪا ﻣѧﻦ اﻟﻤﻮﺳѧﻢ  أدي وﺻﻮل اﻟﻤѧﺮض ﻟﻠﻐѧﺪد أﻟ  •
  3-51AC  أﻣѧﺎ اﻟﻤﻌѧﺪﻻت اﻟﻌﺎﻟﻴѧﻪ ﻟﻤﻮّﺳѧﻢ .  ﻣﻘﺎرﻧѧﺔ ﻣѧﻊ اﻟﻤﺠﻤﻮﻋѧﻪ اﻟѧﻀﺎﺑﻄﺔAEC
وردت ﻓﻲ اﻟﺤѧﺎﻻت اﻟﺘѧﻲ ﻟѧﻢ ﻳѧﺼﻞ ﻓﻴѧﻪ ﺳѧﺮﻃﺎن اﻟﺜѧﺪي (  10.0<P)ﺑﻤﺴﺘﻮي ﻣﻌﻨﻮﻳﻪ 
 .ﺄﺛﺮﻣﻌﺪﻻت اﻟﻜﻮﻟﺴﺘﺮول اﻟﻜﻠﻴﺔ و اﻟﺠﻠﺴﺮﻳﺪات اﻟﺜﻼﺛﻴﺔ ﻟﻢ ﺗﺘ. ﻟﻠﻐﺪد اﻟﻠﻴﻤﻔﺎوﻳﻪ 
ﻳѧﺆدي ,  ﺳѧﻢ 5ﻓﻠѧﻮﺣﻆ أﻧѧﻪ ﻋﻨѧﺪﻣﺎ ﻳﺰﻳѧﺪ ﺣﺠѧﻢ اﻟѧﻮرم ﻋѧﻦ , أﻣﺎ ﺑﺎﻟﻨﺴﺒﻪ إﻟﻲ ﺣﺠﻢ اﻟѧﻮرم  •
 ﻣﻘﺎرﻧѧѧѧѧѧﺔ ﻣѧѧѧѧѧﻊ أﻟﻤﺠﻤﻮﻋѧѧѧѧѧﻪ 3-51AC و AECذﻟѧѧѧѧѧﻚ إﻟѧѧѧѧѧﻲ ﻣﻌѧѧѧѧѧﺪﻻت ﻋﺎﻟﻴѧѧѧѧѧﻪ ﻣѧѧѧѧѧﻦ 
(. 10.0<P) آﺎن ﻋﺎﻟﻴѧﺎ ﺑﻤѧﺴﺘﻮي ﻣﻌﻨﻮﻳѧﻪ 3-51ACاﻹﺧﺘﻼف ﺑﺎﻟﻨﺴﺒﻪ إﻟﻲ .اﻟﻀﺎﺑﻄﺔ
 .ﺎﺄﺛﺮ أﻳﻀﻣﻌﺪﻻت اﻟﻜﻮﻟﺴﺘﺮول اﻟﻜﻠﻴﺔ و اﻟﺠﻠﺴﺮﻳﺪات اﻟﺜﻼﺛﻴﺔ ﻟﻢ ﺗﺘ
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, ﻋﻠﻲ اﻟﻨﻘﻴﺾ ﻣﻦ ذﻟѧﻚ .ﺗﻘﺮﺣﺎت اﻟﺜﺪي أدت إﻟﻲ ﻇﻬﻮر ﻣﺴﺘﻮﻳﺎت ﻋﺎﻟﻴﻪ ﻓﻲ اﻟﻤﺮﺿﻲ  •
ﻓѧﻲ اﻟﺤѧﺎﻻت ( 10.0<P) إرﺗﻔﺎﻋﺎ ﻋﺎﻟﻴѧﺎ ﺑﻤѧﺴﺘﻮي ﻣﻌﻨﻮﻳѧﻪ 3-51ACﺳﺠﻠﺖ ﻣﻌﺪﻻت 
أﻳѧѧѧﻀﺎ  ﻣﻌѧѧѧﺪﻻت اﻟﻜﻮﻟѧѧѧﺴﺘﺮول اﻟﻜﻠﻴѧѧѧﺔ و . اﻟﺘѧѧѧﻲ ﻟѧѧѧﻢ ﺗﻈﻬѧѧѧﺮ أي ﺗﻘﺮﺣѧѧѧﺎت ﻓѧѧѧﻲ اﻟﺜѧѧѧﺪي 
 .اﻟﺠﻠﺴﺮﻳﺪات اﻟﺜﻼﺛﻴﺔ  ﻟﻢ ﺗﺘﺄﺛﺮ
  ﻣﻘﺎرﻧѧﺔ ﻣѧﻊ AECازات ﺧﻼل اﻟﺤﻠﻤﻪ إﻟﻲ ﻇﻬﻮر ﻣﻌѧﺪﻻت ﻋﺎﻟﻴѧﻪ ﻣѧﻦ أدي وﺟﻮد إﻓﺮ  •
اﻟﺤﺎﻻت اﻟﺘﻲ ﻟﻢ ﻳﻮﺟﺪ ﻓﻴﻬﺎ أي إﻓѧﺮازات , أﻟﻤﺠﻤﻮﻋﻪ اﻟﻀﺎﺑﻄﺔ وﻋﻠﻲ اﻟﻨﻘﻴﺾ ﻣﻦ ذﻟﻚ 
(. 10.0<P) ﺑﻤѧѧﺴﺘﻮي ﻣﻌﻨﻮﻳѧѧﻪ 3-51ACﺧѧѧﻼل اﻟﺤﻠﻤѧѧﻪ ﺳѧѧﺠﻠﺖ ﻣﻌѧѧﺪﻻت ﻋﺎﻟﻴѧѧﻪ ﻣѧѧﻦ 
ﺪات اﻟﺜﻼﺛﻴѧﺔ ﻓﻘѧﺪ أﻣѧﺎ ﺑﺎﻟﻨѧﺴﺒﻪ ﻟﻤﻌѧﺪﻻت  اﻟﺠﻠѧﺴﺮﻳ ,ﻣﻌﺪﻻت اﻟﻜﻮﻟﺴﺘﺮول اﻟﻜﻠﻴﺔ ﻟﻢ ﺗﺘѧﺄﺛﺮ 
أﻇﻬﺮت إﻧﺨﻔﺎﺿﺎ ﻓѧﻲ اﻟﺤѧﺎﻻت اﻟﺘѧﻲ ﻟѧﻢ ﻳﻮﺟѧﺪ ﻓﻴﻬѧﺎ أي إﻓѧﺮازات ﺧѧﻼل اﻟﺤﻠﻤѧﻪ وذﻟѧﻚ 
 ( .10.0<P)ﺑﻤﺴﺘﻮي ﻣﻌﻨﻮي 
 اﻟﻤﻼﺣﻆ ﻓﻲ ﻧﺘѧﺎﺋﺞ هѧﺬﻩ اﻟﺪراﺳѧﻪ أن ﺗﻘѧﺪم اﻟﺤﺎﻟѧﻪ اﻟﻤﺮﺿѧﻴﻪ ﺑﺎﻟﻨѧﺴﺒﻪ ﻟﻤѧﺮض ﺳѧﺮﻃﺎن  •
  .3-51ACاﻟﺜﺪي اﻷوﻟﻲ ﻳﺼﺎﺣﺒﻪ دوﻣﺎ إﻧﺨﻔﺎض ﻣﻌﺪﻻت اﻟﻤﻮﺳﻢ 
 أﻳﻀﺎ أن اﻟﻨﺴﺐ اﻟﻤﺌﻮﻳﻪ ﻟﻠﻤﻌﺪﻻت ﻏﻴﺮ اﻟﻄﺒﻴﻌﻴﻪ اﻟﻌﺎﻟﻴﻪ ﻟﻤﻌﺪﻻت ﻣﻮّﺳﻤﺎت أﻇﻬﺮت هﺬﻩ اﻟﺪراﺳﻪ
 آﺎﻧﺖ ﻣﺮﺗﻔﻌﻪ ﻣﻘﺎرﻧﻪ ﻣﻊ ﻣﻌﺪﻻت اﻟﻜﻮﻟﺴﺘﺮول اﻟﻜﻠﻲ و اﻟﺠﻠﺴﺮﻳﺪات 3-51AC و AECاﻷورام 
ورﺑﻤﺎ ﻣﺰﻳﺪ ﻣﻦ اﻟﺪراﺳﺎت ﻓﻲ ﻣﻮّﺳﻤﺎت اﻷورام وﻓﻲ ﻣﺠﻤﻮﻋﻪ .اﻟﺜﻼﺛﻴﺔ وﻣﻘﺎرﻧﺔ ﻣﻊ اﻟﺪراﺳﺎت اﻟﺴﺎﺑﻘﻪ 
  .ﺗﺄآﺪ هﺬﻩ اﻟﻨﺘﺎﺋﺞ, اﻟﺴﻮداﻧﻴﻴﻦآﺒﻴﺮﻩ ﻣﻦ اﻟﻤﺮﺿﻲ 
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INTRODUCTION 
All studies in the metabolism of cancer cells and experimental approaches 
are based on the assumption that there must be a difference of a biochemical 
nature between normal and malignant cells. If such differences were 
identified, it might aid in the diagnosis and eventually in the evolution of a 
rational chemotherapy for cancer. So far, this approach has been 
disappointing, despite the vast amount of work done. There would seem to 
be two reasons. Firstly, there has been some difficulty in finding a suitable 
system for comparison of normal and cancerous cells; secondly, the right 
problem to tackle, and the right question to ask (Basil, 1985). 
         In the first part of this study, molecules called tumor markers were 
suggested to be measured. Tumor markers are enzymes, proteins and 
hormones produced in abnormal quantities in association with cancer 
(Murray, et al. 2000). They help in detecting, diagnosing, classifying, 
staging, monitoring of therapy and localizing of cancer diseases. But 
unfortunately these tumor markers lack the specificity or in other words, 
when a specific tumor marker can indicate the presence of a specific type of 
cancer disease, appreciable levels of this marker can be detected in other 
types of cancer diseases. Furthermore, we can find them in benign diseases 
such as liver disorders and renal failure. 
The  two types of the breast cancer tumor markers are, one from the 
onco-fetal antigens the carcinoembryonic antigen CEA and the other is one 
of the carbohydrate’s markers, the mucin-associated antigen CA15-3.     
       The precise clinical utilities of these markers have yet to be determined. 
This study is designed to investigate the effect of breast cancer as primary 
and advanced on the plasma levels of the CEA and CA15-3 tumor markers. 
Their levels are going to be compared with other groups of patients having 
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benign breast tumors, other cancer conditions and group of non-cancer 
diseases. 
Previous studies proved that there was an increasing risk of death from 
cancer in subjects with low plasma cholesterol levels (Chao et al., 1975 and 
Feinleib, 1983). This indicates relation between malignancy and lipids 
metabolism. So in the present study, plasma total cholesterol (TC) and 
triacylglycerols (TG) levels are going to be measured in all groups. 
The levels of these parameters, the CEA, CA15-3 and the TC and TG are 
going to be compared in breast cancer conditions considering some clinical 
parameters namely, the size of the tumor, nipple discharge, ulcerations and 
lymph node involvement.       
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CHAPTER ONE 
LITERATURE REVIEW 
1.1.1 Tumor markers 
Tumor markers are molecules occurring in blood or tissue that are 
associated with cancer and whose measurement or identification is useful in 
patient diagnosis or clinical management. The ideal tumor marker is a blood 
test for cancer in which a positive result would occur only in patients with 
malignancy, correlating with the stage and response to treatment and easily 
and reproducibly measured, but unfortunately there is no tumor marker now 
available has met this ideal (Murray et al, 2000).  
Tumor markers can be used for one of four purposes: (1) Screening a 
healthy population or a high risk population for the presence of cancer (2) 
Making a diagnosis of cancer or of a specific type of cancer (3) Determining 
the prognosis in a patient and (4) Monitoring the course of disease in a 
patient in remission or while receiving surgery, radiation, or chemotherapy.               
They are also classified into six groups : onco-fetal antigens carbohydrates, 
enzymes, hormones , non onco-fetal proteins and genetic markers. The 
method by which these tumor markers are measured depends on the type of 
tumor markers, but the most available are the immunoassays (Dion, et al. 
2000). 
It is more realistic, therefore, antigens are being defined on malignant 
cells by their reaction with monoclonal antibodies (Hellstrom, et al. 1982; 
Baldwin, et al. 1983). Even as many of these antigens are proved not to be 
(tumor specific), they are expressed in tumor cells at levels much greater 
than those on normal tissues and so may be used for diagnostic purposes. In 
recent years, immunoassays involving antibodies labeled with a range of 
markers including radioisotopes, fluorescent substances and enzymes have 
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provided tumor detection systems with significant advantages over other 
methods in terms of sensitivity, specificity and reproducibility (Miller, 
1982). Measuring of circulating tumor antigens would be ideal as an 
immunoassay for screening and monitoring of cancer patients. But it has not 
been conclusively established that human tumors express antigens that are 
recognized by the patient, and many investigators question whether this type 
of (neoantigen) is associated with human tumors, at least with sufficient 
frequency to make them suitable targets for immunological screening 
(Baldwin, 1982). Furthermore, few of the reported tumor associated antigens 
have reached a stage where they can be considered for use in cancer 
screening. The large research effort directed towards identifying so-called 
(oncodevelpmental antigens) results from our inability to develop sensitive 
and reproducible assays, which allow quantitative assessment of tumor, 
associated products. This is not a problem in the case of monoclonal 
antibodies, and so considerable attention is being given to their development 
in assays for tumor markers (Evered and Whelan, 1983). 
 Monoclonal antibodies have now been described that are capable of 
reacting with antigens associated with almost all of the major types of 
human solid tumors. Even though many of these are not sufficiently tumor 
specific, they do recognize antigens that are significantly elevated on tumor 
cells. In order to decide their suitability for tumor detection, it is necessary to 
establish whether the antibody-defined tumor cell product is released into 
the circulation, and this in turn requires the design of sensitive and 
reproducible immunoassays. It must also be shown either that the antibody-
defined product is tumor specific, or, more likely, that the body fluid levels 
of the (tumor associated) antigen in cancer patients is significantly elevated, 
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compared with levels in normal individuals or patients with non-malignant 
disease (Baldwin, 1982). 
The release of tumor cell products into the extracellular environment, 
followed by their entry into serum or other body fluids has been investigated 
in some detail. Possible pathways are illustrated in Figure 1 (Price and 
Baldwin, 1977). There is also considerable evidence (particularly from 
animal tumor studies) indicating that tumor membrane products are shed 
into the environment by a complex series of events, including release by 
metabolic processes, as well as by tumor cell lysis. 
Figure 1: Pathway leading to the release of tumor cell surface components 
into the extracellular environment. ( er = endoplasmic reticulum ). (From 
Price and Baldwin, 1977).   
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1.1.2 The Carcinoembryonic Antigen CEA 
  CEA is a complex glycoprotein with a molecular weight of 
approximately 180,000 daltons. This antigen was first discovered in patients 
with adenocarcinoma of the colon in 1965(Gold and Freedman). CEA 
represents a heterogeneous group of molecular species that consist of single 
polypeptide chains with varying carbohydrate components. The ratio of 
protein to carbohydrate varies from 1:1 to 1:5 in CEA molecules from 
different tumors. CEA is a member of a large family of (up to 36) related 
cell surface glycoproteins whose genes (ten located on chromosome 19) can 
be demonstrated in both normal and diseased colonic epithelium. Normally, 
CEA is present in the fetal intestine, pancreas and liver during the first two 
trimesters of gestation. Since the development of a sensitive 
radioimmunoassay for this marker, CEA or CEA-like substances have been 
detected in a variety of non-neoplastic, nonfetal tissues. Normal colonic 
mucosa and pleural and lactating mammary tissue bind to anti-CEA 
antiserum; however, the quantity of CEA or CEA-like molecules expressed 
in these tissues is much less than that observed in malignant tumors 
(Torosian , 1988). 
 CEA is one of the first tumor markers to be identified and 
characterized. Since its discovery, CEA has been evaluated in a wide 
range of malignancies, including breast cancer, and, historically, has 
been considered the standard to which new serum markers are 
compared. Several studies have reported that positive serum CEA 
levels at the time of primary breast cancer diagnosis may represent a 
negative prognostic parameter (Molina, et al. 1998) and correlate 
with the stage of disease (Dnistrian, et al. 1991). Several authors have 
shown that an increase or a decrease in the CEA levels may reflect the 
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status of disease progression or regression (Tormey, et al; 1977. 
Lokich, et al. 1987 and Mughal, et al. 1983). It is suggested that CEA 
may be useful in the postsurgical follow-up of breast cancer patients 
for an early diagnosis of recurrence (al-Jarallah, et al. 1993,Jager, et 
al. 1995 and Ballesta, et al. 1995) and for monitoring response to 
treatment (Jezersek, et al. 1996 and Robertson, et al. 1999). 
 Elevated serum levels of CEA may be found in a variety of 
benign and malignant conditions other than carcinoma of the colon. 
Benign conditions that cause elevated levels of CEA include cigarette 
smoking, gastritis, gastric ulcer, hepatic disease, pancreatitis, benign 
prostatic hypertrophy and renal disease. In these benign conditions, 
elevated levels of CEA are usually transient and moderate in 
magnitude (Torosian, 1988). 
 Clinical practice guidelines for the use of tumor markers in 
breast and colorectal cancer have been published by the American 
Society of Clinical Oncology (1996). For colorectal cancer, CEA 
measurement was recommended preoperatively in cases where the 
level would influence surgical management. For breast cancer, in the 
absence of readily measurable disease, CA15-3 and CEA levels can 
be used to document treatment failure (Dion, et al. 2000).  
  It should be noted that the majority of these studies were 
performed 10–20 years ago. The availability of the CA 15.3 tumor 
marker in the last decade has greatly reduced the value of CEA in 
breast cancer management, and recent studies discourage the routine 
use of the CEA assay because of its low sensitivity in both early and 
advanced diseases compared with CA 15.3 (Safi, et al. 1991 and 
Tondini, et al. 1988).  
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1.1.3 The carbohydrate marker CA15-3 
The CA15-3 antigen, which is also called the MUC-1 gene associated 
antigen (CA15-3), is a high-molecular weight mucin glycoprotein occurs in 
the membranes of normal and malignant epithelial cells of different organs, 
including the breast, lung, ovary and pancreas.  
Mucins are large and complex glycoproteins expressed by several 
epithelial tissues. Mucins have been grouped into seven distinct families 
(MUC1 through MUC7) according to their genetic and biomolecular 
characteristics. MUC1 represents large transmembrane glycoproteins with 
extracellular domains formed of a highly O-linked glycosylated protein core 
consisting of a variable number of highly conserved 20-amino acid repeated 
units (tandem repeats) (Massimo, et al. 1999).  
The human MUC1 gene codes for this mucin glycoprotein that is 
expressed on the ductal cell surface of most glandular epithelia. This 
glycoprotein, also called polymorphic epithelial mucin (PEM), plays a role 
in cell protection and lubrication. In malignant conditions, cell polarity is 
lost such that PEM is expressed on the entire cell surface and is shed into the 
circulation. PEM may also interfere with cellular adhesion and thus play a 
role in the metastatic process (Gijsbert, et al. 1997). Various monoclonal 
antibodies (MAbs) have been raised against epitopes present on this heavily 
glycosylated protein. These Mabs form the basis for the development of 
serum assays valuable in the management of, among others, breast cancer 
patients (Bon, et al.  1990). 
MUC1 mucins are expressed physiologically at the luminal surface of 
glandular epithelia. The expression of MUC1 mucin is up regulated 
frequently, and the protein is released in higher amounts in the blood of 
patients with breast cancer (Massimo, et al. 1999). Several murine 
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monoclonal antibodies reactive with the MUC1 gene product have been 
generated. Some of them have been used to set up immunoassays for the 
detection of the MUC1 mucin in body fluids (Taylor-Papadimitriou, 1991). 
 CA15.3 is the MUC1 marker studied most extensively in breast 
cancer. It is detected by two monoclonal antibodies: 115D8 (Helkins, et al. 
1984), which recognizes a still unidentified epitope, and DF3 (Kufe et al, 
1984), specific for an epitope site on the protein backbone. 
Also the apoprotein of the CA15-3 antigen contains a transmembrane, 
a cytoplasmic and an extracellular, carbohydrate-rich domain. The 
extracellualr domain is polymorphic with a repeat 20-amino acid sequence 
that may vary from 20 to 80 repeats (Massimo, et al. 1999). 
On the other hand, clinically, the CA15-3 level is high in 10-30% of 
non-metastatic breast cancers. The sensitivity of this marker is a function of 
tumor size. Moreover, several abnormal conditions, other than breast cancer, 
may lead to high CA15-3 levels. Thus, in non-cancerous diseases such as 
cirrhosis of the liver and in several cases of hepatitis, a moderate increase 
may be observed. Furthermore, in several other types of cancer, such a 
cancer of the ovary, uterus, pancreas, lung, prostate and colon, an increase in 
CA15-3 may occur. Also in the case of breast cancer the high levels of 
CA15-3, during the post-therapeutic follow-up indicate in 75 to 90% of the 
cases a recurrence or metastasis. 
1.1.4 Studies in measuring CEA and CA15-3 in breast cancer patients 
In various markers, the best single and established marker for breast 
cancer is CA15-3, followed by CEA. Also the correlation between disease 
course and variations in circulating CA15-3 and CEA levels was studied by 
Tondini, et al. (1988). This when they selected fifty-three women with 
metastatic breast cancer for their study and the clinical course was scored as 
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progressive disease (PD), responsive disease (RD), and stable disease on the 
basis of radiological and physical evaluations and by assuming that CA15-3 
levels above 22.0 units/ml and CEA levels above 3.0 ng/ml are elevated 
values and the antigen levels that increased greater than or equal to 25% and 
decreased greater than or equal to 25% from the initial value were 
considered to correlate with PD and RD, respectively. They found that 
CA15-3 was correlated with disease progression, regression, or stability in a 
higher number of patients than CEA (60.3 versus 39.6%; P = 0.02) and the 
CA15-3 have increased greater than or equal to 25% more often than CEA in 
patients with PD (75.0 versus 58.3%) and decreased greater than or equal to 
25% more often than CEA in patients with RD (38.1 versus 23.8%). 
  Also the kinetic patterns of CEA and CA15-3 tumor markers were 
assessed by Kiang, et al. (1990) in 30 patients with advanced breast cancer 
immediately after the initiation of chemotherapy. In their study, they have 
found four distinct kinetic patterns for these tumor markers .Two of them 
fitted the expected relationship where the plasma marker increased during 
tumor progression (nine patients), and declined in tumor regression (five 
patients). The third pattern was paradoxical in that objective tumor 
regression in eight patients was associated with an acute surge of these 
markers followed by a steady decline. The fourth pattern was equally 
paradoxical where tumor progression in eight patients was associated with a 
rapid and transient decline of markers followed by rebounds. They said that 
such a rapid decline might be due to a suppression of marker release.  
Moreover, they recommended that the adequate knowledge of these 
putative paradoxical patterns would permit their effective use in monitoring 
the disease course and perhaps in the early prediction of the therapeutic 
response. 
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In other studies the appearance of non-tumor diseases such as renal 
failure and liver diseases can mislead the study of CEA and CA15-3 levels 
in breast cancer patients. This situation have been encountered by Nicolini, 
et al. (1991) when 2.3% of the non relapsed breast cancer patients were 
falsely suspected of metastases by constant elevation and/or progressive 
increase of CA 15-3 which noticed in them and at the end it was found that 
chronic liver failure, diabetes were the reasons more commonly responsible 
for the CA15-3 increase.   
The relationship between the initial changes of CEA and CA15-3 
tumor markers and the kinetic patterns of these markers after therapy was 
investigated by Sonoo and Kurebayashi (1996). They have noticed that when 
there was a therapeutic response for breast cancer patients, there was an 
increase or decrease of over 20% in CEA and CA15-3 markers, which was 
taken to be significant. 
 Nevertheless, the American Society for Clinical Oncology (ASCO) 
stated in its clinical practice guidelines for the use of tumour markers in 
breast carcinoma (1996) that neither CA 15.3 nor CEA are recommended for 
routine use in screening, diagnosis and surveillance after primary treatment, 
or in monitoring response to treatment, because current literature data are 
insufficient. 
Molina, et al. in 1998 measured CEA and CA15-3  in the sera of 50 
healthy subjects, 58 patients with benign breast diseases, and 413 patients 
with breast cancer (186 locoregional, 185 with advanced disease, and 42 
with no evidence of disease). They found that higher serum levels of the 
tumor markers in patients with nodal involvement or greater tumor size was 
found, but was statistically significant only with CEA (p < 0.01). 
 26
Also in 1998 and 2000 Findeisen, et al. have measured CEA and 
CA15-3 in 314 sera of breast cancer patients and in 58 sera of women 
without breast cancer. They found that, the differences between the control 
group and stages 0-3 were shown to be non-significant for CA 15-3 and 
CEA and significant differences were found in stage 4 for both markers.  
Also in the case of benign breast tumors authors such as Rodriguezde, et al. 
(1995) have reported that the serum levels of the CEA and CA15-3 tumor 
markers did not show significant elevations in benign breast diseases. 
In a long follow-up study Nishimura, et al. (2000) have evaluated the 
relationships between CEA or CA15-3 levels and clinicopathological factors 
or outcomes in patients who had died from recurrent breast cancer. They 
enrolled two hundred-twenty diseased patients who had recurrent or 
advanced breast cancer and who had been treated between 1986 and 2000 in 
a retrospective study and they measured the serum CEA and CA 15-3 for 
them regularly during the clinical course until death. They found that the 
CA15-3 status was one of the significant factors for survival after recurrence 
and might reflect the biological characteristics of tumors, so may be useful 
prognostic predictors in recurrent breast cancer. 
Also Lumachi, et al. (2000) have evaluated the correlation between 
serum tumor markers CEA and CA 15-3 in breast cancer  patients with 
disease relapse and different prognostic parameters at first operation. They 
have found in their study that CEA significantly (p < 0.01) correlated with 
the size of the tumor and axillary node status and CA 15-3 with the age of 
the patients. 
But on the other hand Arslan, et al. (2000) reported that both CEA 
and CA15-3 showed no statistically significant correlation with either the 
number of invaded axillary lymph nodes or tumor size. This when they 
 27
investigated the correlation, if there is any, of the levels of CA15-3, CEA 
and prolactin in patients with breast cancer with the most commonly used 
prognostic factors. 
The utility of computer stimulation models to compare the 
performance of CEA and CA15-3 tumor markers in defining progression or 
nonprogression of metastatic breast cancer was investigated by Soletormos,  
et al. (2000). 
Soletormos and Schioler, (2000) have developed a computer program 
that facilitates the monitoring of individual breast cancer patients with CEA 
and CA15-3 tumor markers measurements. Their program was simply a 
software package which contains a database that can store the interpretation 
of the measurements as evaluation codes together with patient information 
about treatment type, dates for treatment periods, control periods, and 
evaluation codes for clinical activity of disease.  
Also there is some evidences that the vaccination of breast and 
ovarian cancer by dendritic cells (DCs) and a single tumor antigen such as 
MUC1-derived peptides (Brossart, et al. 2000) may induce immunologic 
responses which may be relevant to the design of future clinical trials of 
other peptide-based vaccines. 
Canizares, et al. (2001) stated that the preoperative values of CA15-3 are 
highly associated with the number of positive lymph nodes. This when they 
were determined the preoperative values of CEA and CA15-3 in 364 breast 
cancer patients with no clinical signs of metastasis in order to know the 
prognostic value of both tumor markers. 
Other researchers such as Guadagni, et al. (2001) who considered the 
CEA monitoring as an expensive and inefficient method of follow-up 
evaluation for breast cancer patients, which provides no additional value 
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when used in combination with CA15-3. This was the case when they 
monitored five hundred and forty-nine patients during postsurgical follow-
up for either a minimum of 5 years or until time of recurrence and also 
monitored fifty-three patients with metastases during chemotherapy. 
In 2003, when the CEA and CA15-3 levels were studied in the sera of 
1057 untreated patients with locoregional breast cancer diagnosed from 1983 
to 2001in a prospective study done by Molina, et al. (2003a). They found 
that there were abnormal levels of CEA and CA15-3 in 13% and 18.8% of 
the patients, respectively. They also found that both tumor markers correlate 
with the tumor size and the nodal involvement and the CEA was also related 
to the histological type and the CA 15.3 with the histological grade. 
In another study Molina, et al. (2003 b) found abnormal levels of 
CEA (12 %) and CA15-3 (13%) in the sera of 503 untreated patients with 
breast cancer diagnosed from 1988 to 2000. In this study they also found 
that CEA and CA15-3 were correlated with tumor size and nodal 
involvement and the CEA alone was related to menopausal status. 
In order to evaluate the importance of the preoperative plasma CA 15-
3 and carcinoembryonic antigen (CEA) levels and how it can add to the 
doctors knowledge about the prognosis of breast cancer patients when the 
conventional histopathologic prognostic factors (tumor grade, lymphatic 
infiltration, stromal invasion, vessel invasion, tumor necrosis, elastosis, and 
number of positive lymph nodes) was determined. Seker, et al. (2003) 
examined the serum tumor marker levels and the histopathology results of 
29 patients and after statistical calculations, he concluded that preoperative 
serum CA 15-3 levels can be taken into consideration when evaluating the 
prognosis because the CA 15-3 level is directly and positively correlated 
with the number of positive lymph nodes. 
 29
1.2.1 Cholesterol and cancer 
A number of epidemologic studies have been published in recent 
years showing an increased risk of death from cancer in subjects with low 
plasma cholesterol levels (Committee of principal investigators, 1978 and 
Feinleib, 1983). Although several authors propose that hypocholesterolemia 
is a predisposing factor for cancer development (Rose, et al. 1974 and 
Beaglehole, et al. 1980) no causative relation has been established so far and 
it may well be that low plasma cholesterol is secondary to malignant disease. 
The latter possibility is supported by studies in which the inverse relation 
between plasma cholesterol and the risk of death from cancer disappeared in 
patients with cancer, followed-up within two years after cholesterol 
determination (Cambien, et al. 1980 and Rose and Shiply, 1980).    
Cholesterol homeostasis in healthy subjects depends on the presence 
and function of specific receptors on the cell surface. These receptors 
normally control the degradation of low-density lipoproteins (LDL), the 
major cholesterol transport protein in human plasma. On the other hand 
there is evidence that, in neoplastic disease, an increased LDL receptor 
activity in tumor cell may produce hypocholesterolemia (Vitlos, et al. 1985).  
Chao, et al. (1975) reported a decline in the serum albumin and 
cholesterol levels in cancer patients and that these patients usually died when 
their levels were lower than half of the initial levels. This when they tried to 
describe the usefulness of serum proteins, albumin, and cholesterol levels in 
assessing the course and prognosis in cancer patients. 
Also Alexopoulos, et al. (1987) concluded that either 
hypocholesterolemia is a secondary phenomenon to cancer process or its 
contribution to cancer development, if any causative relation exists, is very 
small. When they measured total serum, free and esterified cholesterol, high-
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density lipoproteins (HDL) cholesterol and serum lipoproteins in 103 
consecutive cancer patients (60 men and 43 women; mean age, 56 years) and 
100 age-matched noncancer inpatients. In their study they found that the 
cancer patients as a group demonstrated significantly lower total cholesterol, 
esterified cholesterol and LDL cholesterol, compared with noncancer 
patients, but breast cancer was proved to be an exception associated with 
increased serum total cholesterol, free cholesterol and LDL cholesterol.  
1.2.2 Breast cancer and cholesterol 
In a comparative study of pre- and postmenopausal women with 
benign and malignant breast disease, Bani, et al. (1986) have observed a 
number of differences in the levels of circulating plasma prolactin and lipid 
concentrations. They found that, plasma lipids, phospholipids, triglycerides, 
cholesterol and free fatty acids were all higher in blood obtained from breast 
cancer patients prior to surgery, while HDL-Cholesterol levels were 
significantly lower in these patients.  At the same time, it was reported in 
another study by Howson, et al. (1986) that this elevation in serum 
cholesterol, either alone or in combination with overweight, have no 
association with the tumor stage or tumor size. 
Also the higher levels of total cholesterol in breast cancer patients 
compared with controls were found by Gerber, et al. (1989). When they 
analyzed the intake of vitaminE, total lipids, total cholesterol, and fatty acids 
with the blood levels of vitamin E, total cholesterol, triglycerides, and the 
serum distribution of fatty acids in a hospital-based population of 120 
patients and 109 controls. Their study showed that, high serum cholesterol, 
in combination with overweight is to be associated with decreased survival 
in breast cancer. Kokoglu, et al. (1994) quantified total cholesterol, high-
density lipoprotein (HDL), low-density lipoprotein (LDL), and very-low 
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density lipoprotein (VLDL) cholesterol levels in Stage I and Stage IV breast 
cancer patients in order to evaluate the changes in serum lipids and 
lipoproteins in the early and advanced stages of the disease when compared 
with data from age-matched healthy females. In their study fasting serum 
VLDL cholesterol levels were found to be significantly increased and HDL 
cholesterol levels significantly decreased in patients with breast cancer. 
Furthermore, a significant increase in VLDL cholesterol and decreases in 
total, HDL and LDL cholesterol levels were demonstrated in patients with 
Stage IV disease when compared to those with Stage I breast cancer. In 
addition to that, no significant difference was found in total and LDL 
cholesterol between Stage I breast cancer patients and healthy controls. 
In recent studies Han, et al. (2005) found that serum HDL-C levels 
were lower in patients with breast cancer than in patients with benign breast 
disease and healthy controls. This when they investigated whether there is a 
relationship between serum levels of lipids and breast cancer incidence, in 
order to find experimental evidence that would be helpful in the diagnosis 
and prevention of breast cancer. As conclusion, they reported that, the 
reduced level of serum HDL-Cholesterol may be correlated with increased 
risk of breast cancer, suggesting that one way of preventing breast cancer 
would be carried out by controlling the intake of food. 
1.2.3 Serum Triglycerides and Breast Cancer 
The high serum triglycerides in breast cancer patients was reported by 
several authors such as Alexopoulos, et al. (1987) who measured serum 
lipids and serum lipoproteins in 103 consecutive cancer patients (60 men and 
43 women; mean age, 56 years) and 100 age-matched noncancer inpatients. 
The same result was found by Bani, et al. (1986) when they investigated the 
circulating plasma prolactin and lipid concentrations in a comparative study 
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of pre- and postmenopausal women with benign and malignant breast 
disease. While Gerber, et al. (1989) reported that there is no difference in 
plasma triglycerides level between breast cancer patients and controls. While 
Kokoglu, et al. (1994) found significant increase in serum triglycerides in 
breast cancer in patients with Stage IV disease when compared to those with 
Stage I breast cancer.  
Moreover, Han, et al. (2005) have reported that elevated serum levels of 
triglyceride may be correlated with increased risk of breast cancer. 
1.2.4 Possible explanations for the low serum cholesterol and cancer 
One of the good research works was done by Stephen and John (1983) 
who analyzed all the studies demonstrating inverse relationships between 
serum cholesterol levels and cancer and similarly the studies not 
demonstrating this relationship. Finally at the end they found that, there are a 
number of ways in which low serum cholesterol levels may be linked to 
cancer. Beside it is possible that the metabolic effects of cancer may 
decrease serum cholesterol, serum cholesterol and lipoproteins might 
directly affect carcinogenesis by the following mechanisms: (1) low serum 
cholesterol may lead to a relatively low plasma membrane cholesterol 
content of T lymphocytes, which could cause poor cell-mediated immune 
function and a greater risk of the development of cancer (Heiniger, et al. 
1978; Abraham, et al. 1980 and Dabrowski, et al. 1980); (2) low serum 
cholesterol may lead to a relatively low plasma membrane cholesterol 
content of other cells, leaving them more susceptible to malignant 
transformation ( Inbar and Shinitsky, 1974); (3)lipoproteins have been 
demonstrated that to modulate immunologic function, although one set of 
experiments would implicate high lipoproteins levels and another set low 
lipoproteins levels as promoters of malignant transformation through 
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immnunologic means (Morse, et al. 1977; Chisari and Edgington, 1975;  
Curtiss and Edginton,  1976;  Curtiss,  et al. 1977 and Chisari,  et al. 1981); 
(4) lipoproteins may be involved in carcinogen transport in the 
bloodstream(Shu and Nichols, 1979). The significance of this to cancer 
causation is unknown. So, although there are several lines of evidence 
linking low serum cholesterol levels to cancer, the hypothesis that low serum 
cholesterol causally related to cancer development is weakly supported.          
Recent studies showed that, low serum HDL-Cholesterol is an 
independent predictor of increased postmenopausal breast cancer risk among 
overweight and obese women (Furberg, et al. 2004). Because low HDL-
Cholesterol is related to increased levels of several cancer-promoting 
hormones (e.g., androgens, estrogens, insulin, and IGF-I). 
In vitro studies have shown that HDL-Cholesterol stimulates the 
growth of human breast cancer cells, especially hormone-independent cells 
(Rotheneder and Kostner, 1989). However, androgens have been found to 
lower HDL-Cholesterol levels in women by regulating the activity of the 
lipolytic enzyme hepatic lipase (Ford and Giles, 2003). Moreover, androgens 
have also been positively associated with breast cancer risk in several studies 
(Dorgan, et al. 1996 and Yu, et al. 2003). 
The observation that there is no strong association between total 
serum cholesterol for breast cancer as it is with HDL-Cholesterol and breast 
cancer. The thing that can be noticed in concentrating all the recent studies 
on HDL-cholesterol. One biologically plausible explanation for this 
difference may be that sex hormones have less influence on total serum 
cholesterol than they do on serum HDL-Cholesterol, which is strongly 
influenced by androgen levels (Gillmer, 1992). 
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1.2.5 The effect of measuring tumor markers beside cholesterol for 
breast cancer patients   
 The use of tumor markers especially the CEA and CA15-3 for breast 
cancer patients, as we know from literature that they correlate with the tumor 
stage, tumor size, and tumor prognosis. Beside they can indicate any sub-
clinical undetectable tumors. 
 In measuring cholesterol levels the use of tumor markers can give 
useful information about the stage of disease, which is better than the 
ordinary clinical breast cancer classification (Alexopoulos, et al. 1987). 
However, it can be a parameter instead of tumor size measuring in breast 
cancer tumors, which is hardly measured in obese patients or clinically 
undetectable tumors.     
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CHAPTER TWO 
MATERIAL AND METHODS 
 2.1 The Patients  
              Permissions, to collect samples from patients, were taken from 
Khartoum educational hospital, Subaa university hospital and Radiation and 
Isotopes Center-Khartoum RICK. The study was performed during the 
period 2004-01-01, until 2004-09-01. One hundred and sixty-five patients of 
different disease conditions were used in this study. 
Group A, Consisted of 30 female patients with breast cancer. The 
malignant tumors in this group were histopathologically confirmed in the 
Sudan National Labrotary of Health (STAC). This includes patients of 
primary, recurrent breast cancer and invasive ductalcarcinoma. The age in 
this group was in the range from 30   to 60 years old.   
Group B, Consisted of 30 female patients histopathologically proven 
of benign tumor of breast such as fibroadenoma or fibro cystic breast 
diseases, that is a benign condition in which there is an abundance of scare 
tissue and small cysts in the breast, which can be confused with cancer. The 
age in this group was in the range from 20  to 60 years old.  
The clinical Parameters for both group A and group B, were taken 
from the patient’s chart in the hospital. These parameters were: (1) the time 
when the condition started (2) The tumor size (in the cm3). (3) The nipple 
discharge. (4) The lymph nodes involvement. (5) The breast ulceration.     
(6) The breast ulceration dimensions. (7) When ulceration of the breast 
started. (8) The painfulness of the tumor and the time when it became 
painful. (9) The history of using contraceptives. (10) The other descriptions 
of the tumor (e.g., hard or attached to the skin).   
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Group C, Consisted of 15 breast cancer patients but on an advance 
stage. Samples were collected from the patients visiting the Radiation and 
Isotopes Center-Khartoum RICK. The age in this group range from 30   to 
60 years old.   
Group D, Consisted of 30 female patients with benign diseases not 
related to cancer such as patients of liver cirrhosis, chronic renal failure and 
hepatitis. The age in this group range from 30 to 60 years old. 
Group E, Consisted of 30 female patients with malignant diseases 
other than breast cancer such as patients of cancer of the cervix uterine, lung 
cancer, and colorectal cancer, gall bladder and osphogous cancer. The age in 
this group range from 30 to 60 years. 
Group F, Consisted of 30 individuals, without any sign of disease, 
used as control. The age in this group range from   30 to 60 years old.  
 
2.2 Sample Collection 
 From all the 165 patients, 5 ml of blood were taken from each patient 
and kept in their syringes until coagulation, then serum was separated and 
stored in eppendroff tubes in the freezer at -20 0C, till analyzed for total 
cholesterol, triglycerides and tumor markers CEA and CA15-3. 
In groups A and B the blood samples were taken from them after diagnosis 
just before/or in the day of the surgical operation.  
2.3 Total cholesterol determination 
2.3.1 The principle of the method 
 The cholesterol present in the sample gives rise to a colored complex, 
according to the following reaction: 
      Cholesterol esters    CHE                   Cholesterol + fatty acids 
      Cholesterol + O2            CHOD                    4-Cholestenona  + H2O2 
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2H2O2 + Phenol + 4-Aminophenazone      POD              Quinonimine+4H2O 
The intensity of the color formed is proportional to the cholesterol 
concentration in the sample. 
2.3.2 Reagents 
R 1 
Buffer 
 
Phenol                                     26 mmol/L
R 2 
Enzymes 
Cholesterol esterase (CHE)         300 U/L
Cholesterol oxidase (CHOD)      300 U/L
Peroxidase (POD)                     1250 U/L 
4-Aminophenazone (4-AP)    0.4mmol/L 
CHOLESTEROL 
CAL 
Cholesterol aqueous primary standard  
200mg/dl 
 
2.3.3 Preparation 
In order to prepare the working reagent (WR) the contents of one vial 
R 2 enzymes were dissolved in one bottle of R 1 Buffer. It must be caped 
and mixed gently to dissolve contents. 
2.3.4 Additional equipments 
-CORNING Colorimeter 253-Germany 
-Matched cuvettes 1.0 cm light path. 
-General laboratory equipments. 
2.3.5 Procedure 
   a.  Assay conditions: 
         Wave length:………………………505 nm (500-550). 
          Cuvette:……………………………1 cm light path. 
          Temperature:………………………370C /15-250C. 
             b.  The instrument was adjusted to zero with distilled water. 
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             c.  Then into the cuvettes the following reagents were pipetted:  
 Blank Standard Sample 
WR (ml) 1.0 1.0 1.0 
Standard (µL) -- 10 -- 
Sample (µL)  -- -- 10 
             d.  Then the cuvettes were mixed and incubated for 5 min. at 37 0C 
or 10 min. at room temperature. 
      e.  The absorbance (A) of the samples and standard was read against 
the blank. The colour should be stable for at least 60 
minutes. 
2.3.6 Calculations 
(A) Sample          x      200 (Standard conc.)    = mg/dl cholesterol in 
the (A)Standard                                                              sample    
2.4 Triglyceride determination 
2.4.1 The principle of the method 
Samples for triglycerides determination incubated with 
lipoproteinlipase (LPL), liberate glycerol and free fatty acids. 
Glycerol is converted to glycerol-3-phosphate (G3P) and adenosine-5-
diphosphate (ADP) by glycerol kinase and ATP. Glycerol-3-
phosphate (G3P) is then converted by glycerol phosphate 
dehydrogenase (GPO) to dihydroxyacetone phosphate (DAP) and 
hydrogen peroxide (H2O2).  
In the last reaction, hydrogen peroxide (H2O2) reacts with 4-
aminophenazone (4-AP) and p-chlorophenol in presence of 
peroxidase (POD) to give a red colored dye: 
 
             Triglycerides + H2O        LPL                    Glycerol + free fatty acids 
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             Glycerol + ATP    Glycerol kinase            G3P + ADP 
             G3P + O2          GPO              DAP + H2O2 
                    H2O2 + 4-AP + p-Chlorophenol     POD               Quinone + H2O 
2.4.2 Reagents 
R 1 
Buffer 
 
p-chlorophenol                              2 mmol/L 
R 2 
Enzymes 
Lipoprotein lipase (LPL)          150000 U/L 
Glycerol kinase (GK)                      500 U/L 
Glycerol-3-oxidase (GPO)            2500 U/L 
Peroxidase (POD)                            440 U/L
4-Aminophenazone (4-AP)        0.1 mmol/L
ATP                                            0.1 mmol/L
TRIGLYCERIDES 
CAL 
Triglycerides aqueous primary standard  
200mg/dl 
 
2.4.3 Preparation 
In order to prepare the working reagent (WR) the contents of one vial 
R 2 enzymes was dissolved in one bottle of R 1 Buffer. It must be caped and 
mix gently to dissolve contents. 
2.4.4 Additional equipments 
- CORNING Colorimeter 253-Germany 
-Matched cuvettes 1.0 cm light path. 
-General laboratory equipment. 
2.4.5 Procedure 
 a. Assay conditions: 
     Wave length:………………………505 nm (500-550). 
     Cuvette:……………………………1 cm light path. 
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     Temperature:………………………370C /15-250C. 
 b. The instrument was adjusted to zero with distilled water. 
           c.  Then into the cuvettes the following reagents were pipetted: 
  
 
 
 
 
 
  d. Then the cuvettes were mixed and incubated for 5 min. at 37 0C or 
10 min. at room temperature. 
            e. The absorbance (A) of the samples and standard was read against 
the blank. The color should be stable for at least 30 minutes. 
2.4.6 Calculations 
       (A)Sample            x      200 (Standard conc.)    = mg/dl Triglyceride in 
the      (A)Standard                                                            sample    
2.5 Determination of CEA level by the RIA kit 
2.5.1 The principle of the assay 
              CEA procedure is a sequential radioimmunoassay. After 
preincubation of the patient sample with anti-CEA antibody, 125I- 
labeled CEA competes with CEA in the sample for antibody sites. After 
incubation for a fixed time, separation of bound from free is achieved 
by precipitant, followed by centrifugation. The precipitate containing 
the antibody-bound fraction is then counted and patient concentrations 
are read from a calibration curve. 
2.5.2 Material provided  
a. 1 vial of  125I-labeled CEA, red, lyophilized. 
 Blank Standard Sample 
WR (ml) 1.0 1.0 1.0 
Standard 
(µL) 
-- 10 -- 
Sample (µL)  -- -- 10 
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b. 5 vials of CEA standards, lyophilized. 
c. 1 vial of CEA antibody, blue, lyophilized. 
d. 1 bottle precipitation solution (Mixed thoroughly before 
use). 
e. 1 bottle incubation solution. 
2.5.3 Assay procedure 
2.5.3.1 Preparation of reagents 
a. 11 ml of incubation buffer were added into 
125I-CEA, mixed gently until complete 
solution is obtained. 
b. 1 ml of incubation buffer was added in each 
vial of the CEA standards, mixed gently 
until complete solution is obtained (the 
standards, concentrations were as follows 5, 
10, 20, 40 ng/ml.).  
c. 11 ml of incubation solution were added to 
the CEA-antibody, mixed gently until 
complete solution is obtained. 
2.5.3.2 Protocol 
a. The labels were put A-E to the standards, 
(Bo) for the zero-standard, (NSB) for the 
non-specific binding and (S1, S2…Sn) for 
the patient samples. 
b. Then into the appropriate tubes the 
following reagents were piptted 
 NSB Bo Standards Sample 
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Incubation 
solution 
200 µl 100 µl   
Standards   100 µl  
Samples    100 µl 
Antibody  100 µl 100 µl 100 µl 
c. Then all tubes were mixed thoroughly, and 
incubated at 37oC for 2 hours. 
d. 100µl  125I-CEA were dispensed into each 
tubes. 
e. Then it was mixed thoroughly and 
incubated at 37oC for 2 hours. 
f. 500 µl of the precipitant were dispensed 
into each tubes (except the total tubes T 
tubes). 
g. Then it was mixed thoroughly and 
incubated at room temperature for 0.5 
hour. Then all the tubes were centrifuged 
for 20 minutes. 
h. Then the tubes were spinet down and the 
supernatant liquids was discarded. 
i. Finally the remaining activity of all tubes 
was counted. 
2.5.4 Calculations 
The normal range of CEA         (0.00   - 10.00 ng/ml). 
a. The mean count of each group of tubes after subtracting 
the background was calculated. 
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b. Then the standards CPM were plotted against their 
concentrations to draw the standard curve. 
c. The results are obtained by extrapolation from a standard 
curve established at the same time as samples were 
assayed. 
d. The sample values were directly read from the standard 
curve. 
2.6  Determination of CA15-3 level by the IRMA kit 
2.6.1 The principle of the assay 
           The CA15-3 assay is a two-step “ sandwich “ type assay, in which 
two monoclonal mouse antibodies, directed against two different epitopes of 
the molecule, were employed. 
Samples or standards were incubated in tubes coated with the 
monoclonal antibodies, the contents of the tubes were then aspirated and the 
presence of CA15-3 in the sample was revealed by incubation with a second, 
125I-labeled monoclonal antibody. The contents of the tubes were aspirated 
after this second incubation and washing eliminates unbound labeled 
antibody. The amount of bound reactivity measured in a gama counter is 
proportional to the CA15-3 concentration. The unknown values were 
determined by interpolation from a standard curve. 
2.6.2 Reagents provided 
      a. Monoclonal 125I-labelled anti-CA15-3 tracer antibody: one vial, ready-
for-use. The vial contains < 370 kBq (on the date of manifacture) of 
125I-labeled monoclonal antibody with BSA, sodium azide (<0.1%) 
and a dye. 
     b. Tubes coated with anti-CA15-3 antibody: 2*50 tubes, ready-for- use.     
c.  CA15-3 standards A-E: 4 vials  +1 zero standard vial, ready-for use. 
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    The concentration of the standards are A: 11; B: 28; C: 73; 140;E: 230     
U/ml respectively. 
         The standard vials contain human CA15-3 in liquid form with buffer, 
bovine serum albumin and sodium azide (< 0.1%) for the construction 
of a standard curve covering the range from 0 to 250 U/ml. The exact 
concentration is indicated on each vial. 
          d.  Incubation buffer, one vial, ready for use. 
     e.  Diluent or dilution buffer, ready-for-use. 
The flask contains bovine serum albumin in buffer. 
2.6.3 Material required but not provided with the IRMA kit 
In addition to standard laboratory equipment, the following items are 
required: 
a. Precision micropipets (10 μl, 200 μl, 500 μl). 
     b.  Adjustable semi-automatic pipets (200 μl, 2 ml). 
     c.  Vortex mixer. 
d. Reciprocating or oscillating platform shaker (400 rpm). 
e. Aspiration system. 
f. Gamma counter, set for 125I. 
 
2.6.4 Assay procedure 
2.6.4.1 Preparation of reagents 
a. The A-E standards were re-dissolved with 
0.5ml-distilled water. 
b. The samples were diluted 10 times with 
dilution buffer 
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c. All reagents must be brought to room 
temperature. 
d. Antibody-coated tubes were labeled 0 for 
the non-specific binding, A-E for standards 
and S1, S2…Sn for patient samples in a 
single manner.  
e. Another two uncoated tubes were labeled for 
the total count. 
2.6.4.2 Protocol 
a. 200 µl of incubation buffer were dispensed 
into 0 tubes and 150 µl of     incubation 
buffer into all other tubes (except total 
count). 
b. 50 µl of standards or samples (diluted 10 
times) were added to the corresponding 
tubes. 
c. Then the tubes were mixed gently and 
incubated for 2 hours at 37 oC. 
d. The solution of the tubes was aspirated 
completely. Then 1 ml of distilled water was 
added to each tube and decanted or 
aspirated. This step was repeated. 
e. 200 µl of 125I-anti CA15-3 monoclonal 
antibody was added to all tubes. 
f. Then it was mixed gently and incubated for 
3 hours at room temperature. 
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g. Then the solution of the tubes was 
completely aspirated and washed twice with 
1 ml distilled water (except total account). 
h. The tubes were counted for 1 minute. 
2.6.5 Calculations 
The normal range of CA 15-3   (0.00   - 30.00 U/ml) 
e. The mean count of each group of tubes after subtracting 
the background was calculated. 
f. Then the standards CPM were plotted against their 
concentrations to draw the standard curve. 
g. The results are obtained by extrapolation from a standard 
curve established at the same time as samples were 
assayed. 
h. The sample values were directly read from the standard 
curve. 
i. Sample values need not to be corrected for 10 times, this 
because the standards have been corrected for the dilution 
factor. 
2.7  The statistical analysis 
          This was done by the he Independent-Samples T Test 
procedure, which compares means for two groups of cases. Ideally, 
for this test, the subjects should be randomly assigned to two groups, 
so that any difference in response is due to the treatment (or lack of 
treatment) and not to other factors. 
The statistic software used:  SPSS Ver 11 for windows and Excel 200  
(which also was used for recording data and putting it in order). 
In this study two facts were tested: 
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 (A) The least significant difference between the means of total   
cholesterol, triglycerides (TG), CEA and CA15-3 for any group 
of patients compared to the control.  
(B) The means of Total cholesterol, Triglycerides, CEA and CA15-3 
were correlated with the clinical status of the groups (significantly 
different) or not. 
(1) Lymph nodes involvement (yes or no).   
(2) Nipple dischargement (yes or no). 
(3) Breast ulceration (yes or no). 
(4) Tumor size (in the cm3), classified according to TNM staging 
system of tumors which states that: 
                T1============ tumor 2cm or less in greatest dimension. 
                T2============ tumor >2cm and =5 cm in greatest dimension. 
                T3============ tumor >5cm in greatest dimension. 
                T4============ tumor of any size with skin or chest wall. 
 
 
 
 
 
 
 
CHAPTER THREE 
RESULTS 
3.1 The effects of disease condition on plasma total cholesterol, 
triglycerides(TG), CEA and CA15-3 in females are presented in 
table(1) 
 48
3.1.1 Plasma total cholesterol, represented in figure (2).  
It was noticed that the advanced breast cancer (BC) group 
showed the highest value, which is significantly (P < 0.01) different 
from the control. Whereas, it is seven times more than the level of 
other cancer conditions, which are significantly (P < 0.01) lower than 
the control. The primary breast cancer has significantly (P < 0.01) 
lower cholesterol levels compared to the control. Non-tumor diseases 
and the benign breast tumors showed lower cholesterol levels that 
were not significant compared to the control. 
3.1.2. Plasma TG, represented in figure (3).   
The non-tumor diseases showed significantly (P < 0.01) higher 
levels of TG compared to the control. However, the other groups of 
patients showed non-significant difference in TG levels compared to 
control. Furthermore, benign breast tumors and primary breast cancer 
showed similar TG levels to each other and lower compared to the 
control. Similarly, the advanced breast cancer and other cancer 
conditions showed similar TG levels to each other, but higher 
compared to the control. 
3.1.3. Plasma CEA, represented in figure (4).   
The level of the CEA was higher in all disease conditions 
compared to control, but only other cancer conditions, were found to 
have significantly (P < 0.05) higher levels by three times more than 
control. The non-tumor diseases were found to have 2.5 times more 
compared to control. The benign breast tumors and primary breast 
cancer was found to have levels of twice more than the control.  
           The normal range of CEA is (0.00 - 10.00 ng/ml of blood). In 
this study the abnormal levels in all groups were 11 as (36.67 %) of 
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controls, 28 as (93.33 %) of non-tumor diseases, 24 as (80 %) of 
benign breast tumors, 18 as (60 %) of primary breast cancer, 6 as (40 
%) of advanced breast cancer and 25 as (83.33 %) of other cancer 
conditions.      
3.1.4. Plasma CA15-3, represented in figure (5).    
The level of CA15-3 was significantly (P < 0.05) higher in 
primary and advanced breast cancer patients. However, the other 
groups of patients showed non-significantly higher levels compared to 
the control. Furthermore, the primary breast cancer and advance 
breast cancer were having levels of nearly three times compared to 
control. Then other cancer conditions and benign breast tumors have 
1.5 times more and non-tumor diseases of 0.5 times more than the 
control. 
The normal range of CA 15-3 is (0.00 - 30.00 U/ml). In this 
study the abnormal levels in all groups were 2 as (6.67 %) of controls, 
9 as (30 %) of non-tumor diseases, 10 as (33.33 %) of benign breast 
tumors, 13 as (43.33 %) of primary breast cancer, 5 as (33.34 %) of 
advanced breast cancer and 11as (36.67 %) of other cancer conditions. 
 
 
 
 
Table (1): The effect of disease condition on plasma total cholesterol, 
triglycerides(TG), CEA and CA15-3 levels in female patients. 
(Mean ± SE) 
Patients category Total cholesterol TG CEA CA15-3  
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Mean values in the same column with different subscripts letters are 
significantly different. 
   * = (P < 0.05) 
         * * = (P < 0.01) 
 Figure (2): The level of plasma total cholesterol in the different groups of 
patients. 
(mg/dl) 
 
(mg/dl) 
 
(ng/ml) 
 
(U/ml) 
 
 
Control (N=30) 
 
204.20±16.8a 
 
100.15±11.82a 
 
28.36±7.53a 
 
16.28±1.24a 
Non tumor 
diseases (N=30) 
 
175.54±14.17a 
 
 
**192.98±25.73b 
 
68.59±8.68a 
 
25.86±2.47a 
Benign breast 
tumor (N=30) 
 
182.91±17.19a 
 
80.33 ± 14.16a 
 
60.96± 8.05a 
 
31.78±8.11a 
 
Primary breast 
cancer (N=30) 
 
**106.75±11.49b 
 
 
82.38±13.66a 
 
62.29±17.4a 
 
*56.10±13.35b 
 
Advanced breast 
cancer (N=15) 
 
**351.08±25.95b 
 
 
123.95±17.9a 
 
34.11±11.5a 
 
*62.84±20.01b 
Other cancer 
condition 
(N=30) 
 
**54.72±8.06b 
 
 
115.28±13.32a 
 
*91.22±22.48b 
 
35.86±5.91a 
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Figure (3): The level of plasma TG in the different groups of patients.  
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Figure (4): The level of plasma CEA in the different groups of patients. 
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Figure (5): The level of plasma CA15-3 in the different groups of patients. 
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3.2.The effect of lymph node (LN) involvement, in primary breast cancer, on 
total plasma cholesterol, triglycerides (TG), CEA and CA15-3 in 
females is presented in table (2). 
3.2.1. Plasma total cholesterol, represented in figure (6).   
In the Primary breast cancer either when there is LN 
involvement or not, there was no significant difference in the level of 
total cholesterol compared to the control. Furthermore, in primary 
breast cancer in those who have LN involvement their levels of total 
cholesterol were more than the control and those who have no LN 
involvement their levels of total cholesterol were less than the control. 
3.2.2. Plasma TG, represented in figure (7).   
All groups of primary breast cancer patients showed non-
significantly lower levels of TG compared to the control.  
3.2.3. Plasma CEA, represented in figure (8).   
All groups of primary breast cancer patients showed non-
significantly levels of CEA compared to the control. The primary 
breast cancer with no LN involvement showed similar CEA levels to 
the control, while the primary breast cancer with LN involvement 
showed CEA levels double compared to the control. 
3.2.4. Plasma CA15-3, represented in figure (9).   
The level of CA15-3 was significantly (P < 0.01) 2.5 times 
higher in primary breast cancer patients with no LN involvement. 
However, the other groups of patients showed non-significantly 
higher levels compared to the control. Furthermore, the primary breast 
cancer (who have LN involvement) showed non-significantly higher 
levels of CA15-3 compared to the control. 
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Table (2): The effect of lymph node (LN) involvement, in primary breast 
cancer, on total plasma cholesterol, triglycerides (TG), CEA and 
CA15-3 levels in female patients. (Mean ± SE)  
 
Patients category 
 
Total 
cholesterol 
(mg/dl) 
 
TG  
(mg/dl) 
 
CEA  
(ng/ml) 
 
CA15-3  
(U/ml) 
 
 
Control (N=30) 
 
 
204.20±16.8a 
 
100.15±11.81a 
 
28.36±7.53a 
 
16.28±1.24a 
Primary 
breast cancer  
 
LN involvement 
(N=6) 
 
 
 
232.27±33.71a 
 
 
 
67.13±20.88a 
 
 
 
62.49±26a 
 
 
 
28.01±4.73a 
No LN 
involvement 
(N=15) 
 
162.59±20.07a 
 
 
76.16±14.45a 
 
31.02±12.18a 
 
**49.76±9.14b 
 
Mean values in the same column with different subscripts letters are 
significantly different. 
 * = (P < 0.05) 
** = (P < 0.01) 
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Figure (6): The effect of LN involvement, in primary breast cancer, on 
plasma total cholesterol levels. 
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Figure (7): The effect of LN involvement, in primary breast cancer, on 
plasma TG levels. 
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Figure (8): The effect of LN involvement, in primary breast cancer, on 
plasma CEA levels. 
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Figure (9): The effect of LN involvement, in primary breast cancer, on 
plasma CA15-3 levels. 
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3.3. The effect of primary breast cancer tumor size, on the plasma total 
cholesterol, triglycerides (TG), CEA and CA15-3 in females is 
presented in table (3)  
3.3.1. Plasma total cholesterol, represented in figure (10).   
The level of total cholesterol was non-significant lower 
compared to the control, in all tumor size classes on primary breast 
cancer and benign breast tumors patients. Furthermore, the tumor size 
T3 in primary breast cancer showed the highest total cholesterol level, 
and then comes tumor size T4. The lowest total cholesterol level in the 
primary breast cancer was found on tumor size T2. In the benign 
breast tumors, the tumor size T1 in benign breast tumors showed the 
highest total cholesterol level, and then comes tumor size T3. The 
lowest total cholesterol level in the benign breast tumors was found on 
tumor size T2  by a 1/3  of the control.  
3.3.2. Plasma TG, represented in figure (11).   
The level of TG was non-significant lower compared to the 
control, in all tumor size classes on primary breast cancer and benign 
breast tumors patients. A similar TG level to the control was found in 
the tumor size T4 in primary breast cancer. While T2 and T3 in the 
primary breast cancer showed similar TG levels to each other and 
lower than the control. In the benign breast tumors the highest TG 
levels was found in tumor size T1 then T3, which showed 
approximately TG levels of half compared to the control, and T2 
which showed approximately TG levels of 1/3 compared to the 
control. 
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3.3.3. Plasma CEA, represented in figure (12).   
The level of CEA was non-significant compared to the control, 
in all tumor size classes on primary breast cancer and benign breast 
tumors patients. In primary breast cancer tumor size T4, the level of 
CEA was found to be 1.5 times more than control. In the primary 
breast cancer, the tumor size T2 and T3 showed similar CEA levels and 
lower compared to the control. The highest level of CEA was found in 
tumor sizes T1 in the benign breast tumors by 2.5 times than control. 
The T2 and T3 in the benign breast tumors were found to have similar 
values and more than control by two times. 
3.3.4. Plasma CA15-3, represented in figure (13).   
The level of CA15-3 was significantly (P < 0.01) higher only 
on primary breast cancer in the tumor sizes T3 and T4. Where they 
both showed to have similar values and significantly (P < 0.05) higher 
than the control by 2.5 times. In the benign breast tumors, the tumor 
size T1 showed similar value to the control. While T2 and T3 were 
found to have similar values and more than the control.  
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Table (3): The effect of tumor size, in primary breast cancer, on the plasma 
total cholesterol, triglycerides (TG), CEA and CA15-3 levels in 
female patients. (Mean ± SE) 
Patient 
condition 
Tumor size 
Φ  
Total cholesterol 
(mg/dl) 
 
TG 
(mg/dl) 
 
CEA 
(ng/ml) 
 
CA15-3 
(U/ml) 
 
 
Control (N=30) 
 
 
204.20±16.8a 
 
 
100.15±11.82a 
 
28.36±7.53a 
 
16.28±1.24a 
 
  
T2 
 (N=3) 
 
129.53±44.83a 
 
63.63±47.03a 
 
31.97±27.32a 
 
18.47±1.66a 
T3  
(N=10) 
 
185.97±26.88a 
 
64.53±14.23a 
 
35.80±18.82a 
 
**49.93±13.09b 
 
Primary 
breast cancer 
  
 
 
 
       
T4 
 (N=7) 
 
175.16±21.1a 
 
90.73±22.92a 
 
48.36±20.8a 
 
**47.48±7.38b 
 
T1 
 (N=2) 
 
 
170.85±130.65a 
 
 
74.00±32.5a 
 
 
85.71±10.96a 
 
 
18.63±4.9a 
T2 
 (N=4) 
 
67.00±19.91a 
 
 
29.60±7.5a 
 
56.30±19.37a 
 
23.66±4.28a 
Benign breast 
tumors 
 
 
 
 
 
T3 
 (N=5) 
 
136.68±20.6a 
 
42.18±15.68a 
 
 
55.71±24.97a 
 
23.61±8.27a 
 
 
Mean values in the same column with different subscripts letters are 
significantly different. 
   * = (P < 0.05) ;   * * = (P < 0.01) 
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Figure (10): The effect of primary breast cancer tumor size on plasma total 
cholesterol levels. 
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Figure (11): The effect of primary breast cancer tumor size on plasma TG 
levels. 
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Figure (12): The effect of primary breast cancer tumor size on plasma CEA 
levels. 
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Figure (13): The effect of primary breast cancer tumor size on plasma 
CA15-3 levels. 
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3.4. The effect of breast ulceration, in primary breast cancer, on plasma total 
cholesterol, triglycerides (TG), CEA and CA15-3 in females is 
presented in table (4) 
3.4.1. Plasma total cholesterol, represented in figure (14).   
The levels of total cholesterol in primary breast cancer patients 
(either with breast ulceration or not) showed no significant differences 
compared to the control. However, the level of total cholesterol in 
primary breast cancer with breast ulceration showed similar total 
cholesterol levels to the control, while those who have no breast 
ulceration showed little bit lower total cholesterol levels compared to 
control.  
3.4.2. Plasma TG, represented in figure (15).   
The levels of TG in primary breast cancer patients (either with 
breast ulceration or not) showed no significant differences compared 
to the control. In primary breast cancer those who have breast 
ulceration have very similar levels to the control, while those who 
have no breast ulceration showed nearly half of the TG level of  
control. 
3.4.3. Plasma CEA, represented in figure (16).   
 The levels of CEA in primary breast cancer patients (either with 
breast ulceration or not) showed no significant differences compared 
to the control. However, the primary breast cancer patients that have 
breast ulceration showed CEA levels double compared to the control. 
While those who have no breast ulceration have nearly similar CEA 
levels to control.  
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3.4.4. Plasma CA15-3, represented in figure (17).   
The level of CA15-3 was significantly (P < 0.01) higher in by 
more than two times of the control was in the primary breast cancer 
patients that have no breast ulceration. While those who have breast 
ulceration in primary breast cancer have levels of nearly two times 
more than the control. 
Table (4): The effect of primary breast ulceration, in primary breast cancer, 
on plasma total cholesterol, triglycerides (TG), CEA and CA15-3 
levels in female patients. (Mean ± SE) 
Patient 
condition 
Total cholesterol 
(mg/dl) 
 
TG  
(mg/dl) 
 
CEA 
(ng/ml) 
 
CA15-3 
(U/ml) 
 
 
 
 
210.38±67.10a 
 
 
 
 
 
105.26±76.34a 
 
 
 
61.29±65.45a 
 
 
 
29.49±7.86a 
Primary 
breast 
cancer  
Breast 
ulceration 
(N=5) 
 
No breast 
ulceration 
(N=16) 
 
173.78±88.09a 
 
63.68±42.74a 
 
33.37±48.68a 
 
**47.94±35.30b 
 
Control 
(N=30) 
 
204.20±92.02a 
 
 
100.15±64.73a 
 
28.36±41.24a 
 
16.28±6.78a 
Mean values in the same column with different letters from the control are 
significantly different.  * = (P < 0.05)          ;           * * = (P < 0.01) 
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Figure (14): The effect of beast ulceration, in primary breast cancer, on 
plasma total cholesterol levels. 
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Figure (15): The effect of beast ulceration, in primary breast cancer, on 
plasma TG levels. 
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Figure (16): The effect of beast ulceration, in primary breast cancer, on 
plasma CEA    levels. 
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Figure (17): The effect of beast ulceration, in primary breast cancer, on 
plasma   CA15-3 levels. 
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3.5. The effect of nipple discharge, in primary breast cancer, on plasma total 
cholesterol, triglycerides (TG), CEA and CA15-3 in females is 
presented in table (5) 
3.5.1. Plasma total cholesterol, represented in figure (18).   
The levels of total cholesterol in primary breast cancer patients 
(either with nipple discharge or not) showed no significant differences 
compared to the control. In primary barest cancer, those who have 
nipple discharge have showed total cholesterol levels similar to the 
control, while those who have no nipple discharge have lower value 
compared to the control. 
3.5.2. Plasma TG, represented in figure (19).   
The level of TG was significantly (P < 0.05) lower in primary 
breast cancer patients with no nipple discharge. However, the primary 
breast cancer patients with nipple discharge showed non-significantly 
higher TG level compared to the control.   
3.5.3. Plasma CEA, represented in figure (20).   
The levels of CEA in primary breast cancer patients (either with 
nipple discharge or not) showed no significant differences compared 
to the control. The primary breast cancer patients, with nipple 
discharge have CEA levels double compared to the control. The 
primary breast cancer patients with no nipple discharge showed 
similar CEA levels compared to the control. 
3.5.4. Plasma CA15-3, represented in figure (21).   
The level of CA15-3 was significantly (P < 0.01) higher in 
primary breast cancer patients with no nipple discharge. However, the 
primary breast cancer patients with nipple discharge showed non-
significantly higher CA15-3 level compared to the control. 
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Table (5): The effect of nipple discharge, in primary breast cancer, on plasma 
total cholesterol, triglycerides (TG), CEA and CA15-3 levels in 
female patients. (Mean ± SE) 
Patient 
condition 
Total 
cholesterol 
(mg/dl) 
 
TG 
(mg/dl) 
 
CEA 
(ng/ml) 
 
CA15-3 
(U/ml) 
 
 
 
202.68±37.44a 
 
 
 
 
127.43±33.52a 
 
 
76.61±32.2a 
 
 
28.16±4.2a 
Primary 
breast cancer  
Nipple 
discharge 
(N=4) 
 
 
No nipple 
discharge 
(N=15) 
 
 
186.71±22.25a 
 
 
*54.35±8.92b 
 
 
32.45±12.97a 
 
 
**44.21±8.8b 
 
Control 
(N=30) 
 
 
204.20±16.8a 
 
 
100.15±11.82a 
 
28.36±7.53a 
 
16.28±1.24a 
Mean values in the same column with different superscripts letters are 
significantly different. 
 *    = (P < 0.05)   
 * * = (P < 0.01) 
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Figure (18): The effect of nipple discharge, in primary breast cancer, on 
plasma total cholesterol levels. 
normal controlno nipple dischargenipple discharge
ch
ol
es
te
ro
l l
ev
el
s 
(m
g/
dl
)
210
200
190
180
204
187
203
 
Figure (19): The effect of nipple discharge, in primary breast cancer, on 
plasma TG levels. 
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Figure (20): The effect of nipple discharge, in primary breast cancer, on 
plasma CEA levels. 
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Figure (21): The effect of nipple discharge, in primary breast cancer, on 
plasma CA15-3 levels. 
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CHAPTER FOUR 
DISCUSSION 
4.1. The effects of disease condition on plasma total cholesterol, 
triglycerides (TG), CEA and CA15-3 in females.  
4.1.1. Plasma total cholesterol 
In this work, the plasma total cholesterol showed lower levels 
in all disease conditions (except advanced breast cancer) with 
significantly (P<0.01) lower levels in primary breast cancer and other 
cancer conditions. This finding agrees with the result of Han, et al. 
(2005), who found that serum HDL-Cholesterol levels were lower in 
breast cancer patients (p < 0.03) compared with benign breast disease 
and healthy controls and also agrees with the study of Kokoglu et al., 
(1994) which showed that HDL cholesterol levels significantly 
decreased in patients with breast cancer. Furthermore, Kokoglu et al, 
(1994) found a significant increase in VLDL cholesterol and 
decreases in total, HDL and LDL cholesterol levels in patients with 
Stage IV disease when compared to those with Stage I breast cancer. 
While no significant difference was found in total and LDL 
cholesterol between stage-I breast cancer patients and healthy 
controls. On the other hand it disagrees with the study of Bani, et al. 
(1986) who found that, cholesterol was higher in blood obtained from 
breast cancer patients prior to surgery but HDL-Cholesterol levels 
were significantly lower in these patients. This also disagrees with the 
study of Alexopoulos, et al. (1987) who found that breast cancer as an 
exception that having higher levels of cholesterol while other cancer 
patients were found to have significantly lower plasma total 
cholesterol.  
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In the present work, the finding that advanced breast cancer 
showed an exception significantly (P<0.01) higher levels of total 
cholesterol could be attributed to the small number of patients in this 
group (N=15), so more studies are needed with large numbers of 
patients.       
4.1.2. Plasma TG 
           The levels of triacylglycerols in this study were non-
signficantly higher in non-cancer disease, advanced breast cancer and 
the other cancer conditions, but with a highly significantly (P<0.01) 
TG levels in the non-cancer disease conditions. This agrees with the 
study of Alexopoulos, et al. (1987) who found that the breast cancer 
group showed high levels of serum triglycerides, and also agrees with 
the finding of Kokoglu, et al. (1994) who found that serum 
triglycerides are significantly increased when compared with data 
from age-matched healthy females. Similarly in the same study they 
found significant increase in triglycerides in patients with Stage IV 
disease when compared to those with Stage I breast cancer. 
           This agrees with the finding of Bani, et al. (1986) who found that, 
triglycerides were higher in blood obtained from breast cancer 
patients prior to surgery. Also in recent studies Han, et al. (2005) 
found clearly high levels of triglyceride (TG) in patients with breast 
cancer than in patients with benign breast disease and healthy 
controls.  
4.1.3. Plasma CEA 
It was found that the level of the CEA was reported to be higher 
in all disease conditions compared to control, but the only significant 
(P<0.05) difference was found in the group of other cancer conditions 
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patients. This agrees with study of Findeisen, et al. (1998) and 
Findeisen,  et al. (2000) who found that the differences between the 
control group and stages 0-3 for breast cancer patients were shown to 
be non-significant for CEA but in the same time it does not agree with 
their finding that, the significant differences were found in stage 4 for 
the same CEA tumor marker. The result that the benign breast tumors 
has no significant difference with the control agrees with the study of 
Rodriguez, et al. (1995) who found that the serum levels of CEA 
tumor marker did not show significant elevations in benign breast 
diseases. 
The abnormal levels of CEA measured in this study were as 
follows: 18 of 30 in primary breast cancer as 60 %, 6 of 15 in 
advanced breast cancer as 40 %. While scientists such as Molina et 
al., (2003 b) found abnormal CEA serum levels in 13% of the 
patients, for 1057 untreated patients with locoregional breast cancer 
diagnosed from (1983) to (2001). Also in another study done by 
Molina, et al. (2003 a) the abnormal levels were found for CEA in 
12% of 503 untreated patients with breast cancer diagnosed from 
(1988) to (2001). 
4.1.4. Plasma CA15-3   
It has been shown that the CA15-3 showed also higher levels in 
all disease conditions compared to control and in the primary and 
advanced breast cancer conditions, the levels were significantly higher 
(P<0.05) compared to control. This disagrees with study of Findeisen, 
et al.(1998) and Findeisen, et al. (2000) who found that the 
differences between the control group and stages 0-3 for breast cancer 
patients were shown to be non-significant for CA15-3 but in the same 
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time it agree with their finding that, the significant differences were 
found in stage-4 for the same CA15-3 tumor marker. Also the result 
that the benign breast tumors has no significant difference with 
controls agrees with the study of Rodriguez et al., (1995) who found 
that the serum levels of CA15-3 tumor marker did not show 
significant elevations in benign breast diseases. 
However, the clinical practice guidelines for the American 
Society for Clinical Oncology (ASCO) for the use of tumor markers 
in breast carcinoma, (1996) stated that neither CA 15.3 nor CEA are 
recommended for routine use in screening, diagnosis and surveillance 
after primary treatment, or in monitoring response to treatment, 
because current literature data are insufficient.   
In the case of abnormal levels of CA15-3 measured in this 
study it was 13 of 30 (43.33 %) in primary breast cancer, 5 of 15 
(33.34 %) in advanced breast cancer. While Molina et al., (2003 b) 
found abnormal CA 15.3 serum levels in 18.8% of the patients, for 
1057 untreated patients with locoregional breast cancer diagnosed 
from (1983) to (2001). Also in another study done by Molina, et al. 
(2003 a) the abnormal levels were found for CA 15.3 in 13% of 503 
untreated patients with breast cancer diagnosed from (1988) to (2001). 
4.2. The effect of lymph node (LN) involvement, in primary breast cancer, 
on total plasma cholesterol, triglycerides (TG), CEA and CA15-3 in 
females.  
4.2.1. Plasma total cholesterol 
The levels of total cholesterol in the Primary breast cancer 
either with LN involvement or not showed no significant difference 
compared to the control. However, the cholesterol levels were not 
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affected. Since there was no study showing the correlation between 
total cholesterol levels and LN involvement, so it is found suitable to 
be compare this findings with that was done without referring to any 
clinical parameter. The levels of total cholesterol in breast cancer 
patients with no LN involvement, showed lower non-significantly 
compared with the studies that showing significant decrease in 
cholesterol levels (Kokoglu, et al. 1994) and (Han, et al. 2005).      
4.2.2. Plasma TG 
The levels of TG in patients with either LN involvement or not 
showed non-significantly lower levels of TG compared to the control. 
Since there was no study found showing the correlation between TG 
levels and LN involvement, so it is found suitable to be compare this 
findings with that was done without referring to any clinical 
parameter. The levels of TG in breast cancer patients with no LN 
involvement showed non-significantly slightly higher levels compared 
with the studies that showing significant increase in TG levels 
(Alexopoulos, et al. 1987; Kokoglu, et al. 1994; Bani, et al. 1986 and 
Han, et al. 2005).   
4.2.3. Plasma CEA 
The CEA levels in the present work either with LN 
involvement or not, showed non-significantly difference compared to 
the control. This does not agree with the two studies of Molina,  et al. 
(2003a) and Molina, et al. (2003b) who found that CEA tumor marker 
was correlated with nodal involvement with significantly higher 
concentrations. But it agrees with the study of Arslan, et al. (2000) 
who reported that CEA levels showed no statistically significant 
correlation with the number of invaded axillary lymph nodes. Also, it 
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does not agree with the study of Lumachi, et al. (2000) who found 
that CEA significantly (p < 0.01) correlated with axillary node status. 
However, Molina, et al. (1998) reported with higher serum levels in 
patients with nodal involvement was statistically significant only with 
CEA (p < 0.01). 
4.2.4. Plasma CA15-3 
In this study, the primary breast cancer patients that have no LN 
involvement are the only group, which showed significantly (P > 
0.01) higher levels of CA15-3 compared to the control. This disagrees 
with the two studies of Molina, et al. (2003a) and Molina, et al. 
(2003b) in which they found that CA15-3 tumor marker was 
correlated with nodal involvement with significantly higher 
concentrations in these patients. Also this agrees with the study of 
Canizares, et al. (2001) who reported that the preoperative values of 
CA15-3 were highly associated with the number of positive lymph 
nodes. But on the other hand it does not agree with the study of 
Arslan, et al. (2000) who reported that CA15-3 levels showed no 
statistically significant correlation with the number of invaded axillary 
lymph nodes. This also found in the study of Molina, et al. (1998) 
who reported that higher serum levels of CA15-3 in patients with 
nodal involvement was found, but with no significant difference. 
In summary, it must be notice that the levels of cholesterol, 
triacylglycerols and CA15-3 in patients with no LN involvement (low 
cholesterol, higher triacylglycerols and higher CA15-3 levels) are 
similar to the findings of studies that was done without referring to 
any clinical parameter. The finding, which needs more attention here, 
 76
that the LN involvement increases, total cholesterol, reduces 
triacylglycerols and decreases the CA15-3 levels.     
4.3. The effect of primary breast cancer tumor size, on the plasma total 
cholesterol, triglycerides (TG), CEA and CA15-3 in females.  
4.3.1. Plasma total cholesterol 
In the present work, all tumor classes showed no significant 
difference in the total cholesterol levels compared to control in both 
primary breast cancer and benign breast tumors. So the levels of 
plasma total cholesterol were not affected by tumor size. There was no 
study found showing the correlation between plasma total cholesterol 
levels and tumor size. When, all levels were lower but there was no 
significant decrease, more studies are needed in order to compare 
these findings with the studies, that reported without referring to any 
clinical parameter, which showed significant decrease in cholesterol 
levels (Kokoglu, et al. 1994) and (Han, et al. 2005).   
4.3.2. Plasma TG 
           Similarly, in all tumor classes there was no significant 
difference in the TG levels compared control in both primary breast 
cancer and benign breast tumors. So the levels of plasma triglycerides 
were not affected by tumor size. When there was no study found 
showing the correlation between total cholesterol levels and tumor 
size, so it is found suitable to be compare this findings with that was 
done without referring to any clinical parameter. But these levels 
disagree with the studies which showing the significant increase in TG 
levels (Alexopoulos, et al. 1987; Kokoglu, et al. 1994; Bani, et al. 
1986 and Han, et al. 2005). 
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4.3.3. Plasma CEA 
In all tumor size classes, no significant difference in the level of 
CEA compared to control. This agrees with the study of Arslan, et al. 
(2000) who reported that CEA levels showed no statistically 
significant correlation with the tumor size. However, this does not 
agree with the two studies of Molina, et al. (2003a) and Molina, et al. 
(2003b) in which they found that CA15-3 tumor marker was 
correlated with tumor size with significantly higher concentrations in 
patients with larger tumors. Similarly, it does not agree with the study 
of Lumachi, et al. (2000) who found that CEA significantly (p < 0.01) 
correlated with the size of the tumor. But it does not agree with the 
study of Molina, et al. (1998) who said that higher serum levels in 
patients with greater tumor size was statistically significant only with 
CEA (p < 0.01). 
4.3.4. Plasma CA15-3 
The significantly (P > 0.01) higher concentrations of CA15-3 in 
the primary breast cancer patients with large size tumors (tumor size 
T3 and T4) in this study, were found to agree with the two studies of 
Molina, et al. (2003a) and Molina, et al. (2003b) in which they found 
that CA15-3 tumor marker was correlated with tumor size with 
significantly higher concentrations in patients with larger tumors. 
But this does not agree with the study of Arslan, et al. (2000) who 
reported that CA15-3 levels showed no statistically significant 
correlation with the tumor size. This finding reported by Molina, et al. 
(1998) who reported that higher serum levels of CA15-3 in patients 
with greater tumor size was found, but with no significant difference. 
 78
So in general, while the levels of cholesterol and triacylglycerol 
in breast cancer patients were not affected by the tumor size, it was 
found that when the size is larger than 5 cm, it results in higher levels 
of CA15-3 compared to control.     
4.4. The effect of breast ulceration, in primary breast cancer, on plasma total 
cholesterol, triglycerides (TG), CEA and CA15-3 in females. 
4.4.1. Plasma total cholesterol  
In primary breast cancer patients either with breast ulceration or 
not, no significant difference were found in the total cholesterol levels 
compared to the control. Since there was no study found showing the 
correlation between total cholesterol levels and breast ulcerations, so 
it is suitable to be compare this with the studies, which were done 
without referring to any clinical parameter. The levels of breast cancer 
patients with no breast ulceration showed lower but not significant 
levels, so more studies is needed in order to compare this findings 
with the studies, that showing the significant decrease in cholesterol 
levels (Kokoglu, et al. 1994) and (Han, et al. 2005). 
4.4.2. Plasma TG 
           The plasma TG levels in patients with either breast ulceration or 
not showed non-significantly difference compared to the control. 
Since there was no study found showing the correlation between TG 
levels and breast ulcerations, so it is suitable to compare this with the 
studies, which were done without referring to any clinical parameter. 
The patients with breast ulceration have higher TG levels, the thing 
which agree with the studies that showing significant increase in TG 
levels (Alexopoulos, et al. 1987; Kokoglu, et al. 1994; Bani, et al. 
1986 and Han, et al. 2005).     
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3.4.3. Plasma CEA 
            The plasma CEA levels in patients with either breast ulceration 
or not there showed non-significantly difference compared to the 
control. Since there was no study found showing the correlation 
between CEA levels and breast ulcerations, so it is suitable to 
compare this with the studies, which were done without referring to 
any clinical parameter. So this finding was found to agree with the 
study of Findeisen, et al. (1998) and Findeisen, et al. (2000) who 
found that the differences between the control group and stages 0-3 
for breast cancer patients were shown to be non-significant for the 
levels of CEA but at the same time it disagree with their finding that, 
the significant differences were found in stage-4 for the same CEA 
tumor marker. 
 4.4.4. Plasma CA15-3 
Only the primary breast cancer patients with no breast 
ulceration, which showed significantly (P < 0.01) higher levels of 
plasma CA15-3 levels twice compared to the control. Since there was 
no study found showing the correlation between CA15-3 levels and 
breast ulcerations, so it is suitable to compare this with the studies, 
which were done without referring to any clinical parameter.  So this 
finding was found to disagree with the study of Findeisen, et al. 
(1998) and Findeisen, et al. (2000) who found that the differences 
between the control group and stages 0-3 for breast cancer patients 
were shown to be non-significant for the levels of CA15-3 but in the 
same time it agree with their finding that, the significant differences 
were found in stage-4 for the same CA15-3 tumor marker. 
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In summary, it must be noticed that the levels of cholesterol, 
triacylglycerols and CA15-3 on patients with no breast ulceration (low 
cholesterol and significantly (P<0.01) higher CA15-3 levels are 
similar to the findings of studies that was done without referring to 
any clinical parameter. The finding, which needs more attention here 
that the breast ulceration increases the CEA and CA15-3 levels. While 
the levels of total cholesterol and TG levels were not affected.  
4.5. The effect of nipple discharge, in primary breast cancer, on plasma total 
cholesterol, triglycerides (TG), CEA and CA15-3 in females.  
4.5.1. Plasma total cholesterol 
In primary breast cancer patients either with nipple discharge or 
not, no significant difference were found in total cholesterol levels. 
Since there was no study found showing the correlation between total 
cholesterol levels and nipple discharge, so it is suitable compare this 
with the studies, which were done without referring to any clinical 
parameter. The levels of total cholesterol in breast cancer patients 
with no nipple discharge showed non-significantly lower levels, 
compared with the studies, that showing significant decrease in 
cholesterol levels (Kokoglu, et al. 1994) and (Han, et al. 2005).  
4.5.2. Plasma TG 
Only the patients with no nipple discharge have significantly 
(P<0.05) lower levels of TG compared to the control. Since there was 
no study found showing the correlation between TG levels and nipple 
discharge, so it is suitable to be compare this findings with that was 
done without referring to any clinical parameter.  So this finding was 
found not to agree with studies that showed significant increase in TG 
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levels (Alexopoulos, et al. 1987; Kokoglu, et al. 1994; Bani, et al. 
1986 and Han, et al. 2005). 
4.5.3. Plasma CEA   
             The plasma CEA levels in patients with either nipple discharge 
or not there showed non-significantly difference compared to the 
control. Since there was no study found showing the correlation 
between CEA levels and nipple discharge, so it is suitable to compare 
this with the studies, which were done without referring to any clinical 
parameter. So this finding was found to agree with the study of 
Findeisen, et al.  (1998) and Findeisen, et al. (2000) who found that 
the differences between the control group and stages 0-3 for breast 
cancer patients were shown to be non-significant for the levels of 
CEA but in the same time it disagree with their finding that, the 
significant differences were found in stage-4 for the same CEA tumor 
marker. 
4.5.4. Plasma CA15-3 
Only the primary breast cancer patients with no nipple 
discharge, which showed significantly (P < 0.01) higher levels of 
plasma CA15-3 levels twice compared to the control. Since there was 
no study found showing the correlation between CA15-3 levels and 
nipple discharge, so it is found suitable to be compare this findings 
with that was done without referring to any clinical parameter.  So this 
finding was found to disagree with the study of Findeisen, et al. 
(1998) and Findeisen, et al. (2000) who found that the differences 
between the control group and stages 0-3 for breast cancer patients 
were shown to be non-significant for the levels of CA15-3 but in the 
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same time it agree with their finding that, the significant differences 
were found in stage-4 for the same CA15-3 tumor marker. 
In summary, it must be noticed that the levels of cholesterol, 
triacylglycerols and CA15-3 in patients with no nipple discharge (low 
cholesterol and significantly (P<0.01) higher CA15-3 levels are 
similar to the findings of studies that was done without referring to 
any clinical parameter. The finding, which needs more attention here 
that the nipple discharge increases the CEA and CA15-3 levels. While 
the levels of total cholesterol and TG levels were not affected. 
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Conclusions 
Findings in this study agree with the majority of the previous 
studies in that, breast cancer has significantly low levels of total 
cholesterol and significantly high levels of triglycerides. 
So, it is recommend investigating out the cholesterol fractions 
and lipoprotiens with a long follow-up in order to answer the 
question that whether the decline in serum cholesterol in cancer 
patients is the cause of malignancy or it is simply a result of it. 
Findings in the present work suggest a reduction of the levels of 
CA15-3 tumor marker when the case of breast cancer is advanced. 
It was found that nipple dischargement and breast ulceration 
have steady and similar levels for total cholesterol, CEA and CA15-
3 tumor markers, which makes them suitable targets for further 
studies. 
The percentages of patients, who recorded abnormally high 
levels of the tumor markers CEA and CA15-3, from the total of 
breast cancer patients, were higher compared to values reported in 
previous studies. Further studies exploring about tumor markers, in 
larger numbers of Sudanese patients, may confirm this finding.  
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